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Exposure to the potent synthetic estrogenic compound diethylstilbestrol (DES) 
during early development has been found to elicit numerous detrimental effects. 
Prescribed to millions of pregnant women from the 1930s to the 1970s, it has been shown 
that exposure to DES caused significant reproductive organ abnormalities and 
dysfunction in both men and women (DES sons and daughters, respectively) who were 
exposed in utero. A high incidence of psychiatric disorders has also been reported, 
primarily in adult DES daughters. Because of estrogen’s well-known influence on 
emotion, it has been suggested that exposure to this estrogenic compound may be able to 
disturb the normal regulation of behaviors modulated by estrogen and estrogen receptors 
(i.e., emotion-related behaviors). The current study investigated the effects of gestational 
DES exposure on anxiety- and depressive-related behaviors during adulthood in female 
mice. Pregnant C57Bl/6 mice were exposed to either vehicle or one of three doses of 
DES (.1, 1.0, or 10.0 µg/kg/day) from gestational day 11 to 17 via oral gavage. Because 
there have been no published reports examining the possible effects of DES exposure 
during pregnancy on the enhancement of postpartum depression and anxiety, associated 
behaviors in the dams were also assessed. Following parturition, all dams were 
ovariectomized. Three female offspring were retained from each litter at weaning. When 
the offspring reached adulthood, one female was ovariectomized, one had a sham 
surgery, and one served as the intact control. Two weeks after surgery (or at a similar age 
in the intact mice), anxiety- and depression-like behaviors were assessed using the 
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Elevated Zero Maze, Open Field, Tail Suspension, and Forced Swim Tests. Overall, the 
results for this study revealed that exposure to DES during late pregnancy did not 
provoke a significant influence over anxiety- and depressive-like behaviors in dams or 
female offspring.  
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Chapter 1:  Introduction 
Defining Endocrine Disrupting Chemicals 
Endocrine disrupting chemicals (EDCs) are compounds that have the ability to 
either mimic or block the normal effects of hormones at the target receptor or tissue; 
EDCs can also exert their effects by stimulating or inhibiting production of endogenous 
endocrine system hormones (U.S. Environmental Protection Agency [U.S. EPA], 2011). 
EDCs can be either synthetic or natural and are able to produce a wide range of adverse 
effects on both behavior and physiology (Patisaul & Adewale, 2009; Schug, Janesick, 
Blumberg, & Heindel, 2011). As such, EDCs alter functions that hormones normally 
control.  
Critical to any EDCs’ ability to elicit harmful effects is the timing of exposure. 
During the sensitive window of perinatal development, fetuses and neonates are 
especially vulnerable to environmental insult (Gore, 2010; Patisaul & Jefferson, 2010; 
Schonfelder, Friedrich, Paul, & Chahoud, 2004). Specifically, during perinatal 
development, normal endogenous estrogens and androgens organize the brain and 
reproductive system in a sexually dimorphic way. This organization causes both 
structural and functional distinctions between males and females that in some cases do 
not become apparent until later in life (Gore, 2008; Gorski, 1985; Palanza, Gioiosa, vom 
Saal, & Parmigiani, 2008; Schwarz & McCarthy, 2008). When exogenous chemicals like 
EDCs are introduced to the developing organism, profound and long-term adverse 
outcomes are probable (Gore, 2008). The “Fetal Basis of Adult Disease” (or FEBAD) 
hypothesis is especially pertinent to neuroendocrine systems (Gore, Heindel, & Zoeller, 
2006; Heindel & Levin, 2005; Patisaul & Adewale, 2009).  
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To further highlight the importance of critical periods of development, it has been 
discovered that exposure to EDCs early in pregnancy can induce different effects 
compared to exposure later in pregnancy or exposure during early childhood (Heindel, 
2007; Schug et al., 2011). Therefore, exposure to EDCs can have not just tissue-specific 
effects, but also time-specific outcomes. It is also important to keep in mind that exposure 
to any given EDC can occur either alone or concurrently with other EDCs or 
environmental stressors, implying that disease etiology may be due to additive or 
synergistic chemical affronts at any point during these critical periods of development 
(Heindel & Newbold, 2009). 
Overview of Diethylstilbestrol 
Diethylstilbestrol, or DES, is a diphenyl compound with numerous toxic effects as 
well as robust estrogenic properties. It has been shown that when administered orally, 
DES is five times more potent than estradiol (Korach, Metzler, & McLachlan, 1978; 
Marselos & Tomatis, 1993). DES is also a well-known EDC that has a notorious history. 
From 1938 to 1971, this potent synthetic estrogen was prescribed to approximately 4 to 6 
million pregnant women in the United States (and between 2 and 10 million women 
worldwide) to prevent miscarriage and promote healthy babies (Patisaul & Adewale, 
2009; Reed & Fenton, 2013). Specifically, it was thought that DES would reduce the risk 
of spontaneous abortion or preterm birth by maintaining placental steroid production 
(Marselos & Tomatis, 1992). Even after a 1953 report about how DES was not successful 
in this regard (Dieckmann, Davis, Ryjenkiewicz, & Pottinger, 1953), there was an 
increase in DES prescriptions for clinical use (Marselos & Tomatis, 1992).  
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However, instead of protecting the developing offspring, DES-exposed children 
(both males and females) experienced adverse reproductive effects (Patisaul & Adewale, 
2009). Vaginal adenocarcinoma, a rare type of cancer, was detected in many women 
whose mothers were given DES during pregnancy - a group now referred to as “DES 
daughters” (Herbst, Green, & Ulfelder, 1970; Herbst, Ulfelder, & Poskanzer, 1971). 
Following the discovery in 1971 that DES was a causal agent in the development of this 
disease, the U.S. FDA prohibited the use of DES for pregnancy care (Couse et al., 2001; 
Herbst, 2000). Not only do DES daughters have an extremely elevated chance of 
developing this form of cancer, they also experience reduced fertility, increased risk of 
infertility, more difficult and failed pregnancies (Goldberg & Falcone, 1999; Palmlund, 
1996; Schug et al., 2011), abnormal anatomy and function of the oviduct and cervix, and 
a T-shaped uterus (Diamanti-Kandarakis et al., 2009; Jefferies et al., 1984). Some of 
these outcomes are thought to occur via binding to ERα and subsequent signaling 
cascades resulting in irregular control of Hox genes (Block, Kardana, Igarashi, & Taylor, 
2000; Couse et al., 2001), which are involved in overseeing the appropriate spatial 
development of the reproductive tract (Block et al., 2000).  
DES sons have also suffered the effects of prenatal exposure to this EDC. They 
exhibit increased incidences of urogenital malformations, undescended testes, testicular 
cancer, and lower sperm mobility and density (Diamanti-Kandarakis et al., 2009; Patisaul 
& Adewale, 2009); such abnormalities are possibly caused by an up-regulation of ERα 
expression in the epididymis (Atanassova et al., 2001). These effects have also been 
observed in animal models (Maranghi, Tassinari, Moracci, Macri, & Mantovani, 2008), 
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further underscoring DES as a causative agent in these disorders (Diamanti-Kandarakis et 
al., 2009).  
Experimental studies employing the use of rodents have demonstrated that 
developmental exposure to DES was the main factor causing the aforementioned 
reproductive malformations. For example, one study using ER knockouts found that 
ERαKO mice exposed to DES from GD 1 to 5 did not display the detrimental 
reproductive tissue phenotypes that wild-types exhibited, suggesting that DES elicits 
many of its effects via binding to ERα (Couse et al., 2001). However, the more specific 
and detailed mechanisms are not as well characterized (Marselos & Tomatis, 1992; 
1993). It is accepted, though, that abnormal estrogen signaling during development is 
quite harmful. Further, the atypical estrogen signaling resulting from DES administration 
is thought to disturb the normal regulation and expression of estrogen-regulated genes 
and eventually the differentiation and proliferation of certain cell populations (Couse et 
al., 2001). 
Timing of DES exposure has also been shown to play a role in the effects in DES 
children. There are considerable disparities in the incidence and degree of the disorders 
associated with DES exposure in utero depending upon timing of first exposure, the total 
dose given, and the duration of exposure (Robboy et al., 1981, 1984). This further 
illuminates the significance of critical periods and increased susceptibility to EDCs 
during perinatal development. 
Problems with reproduction and reproductive organs are not the only struggles 
associated with in utero exposure to DES. DES daughters have also reported higher rates 
of depression and mental health issues (O’Reilly, Mirzaei, Forman, & Ascherio, 2010; 
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Vessey, Fairweather, Norman-Smith, & Buckley, 1983). In animal models, 
developmental DES exposure has been reported to cause altered socio-sexual as well as 
nonsocial behaviors in males and females (Tomihara et al., 2006). Therefore, this 
estrogenic chemical also has the ability to modify behavioral outcomes.  
Importance of Estrogen  
 When having a discussion regarding the effects of exposure to EDCs like DES on 
the brain and behavior, it is also necessary to understand the neurobiological and 
behavioral influence of estrogen (E2; 17β-estradiol) during early development and during 
adulthood. Because DES is a potent estrogen agonist, normal downstream signaling 
results can be altered when DES binds to estrogen receptors (ERs) (Couse et al., 2001). 
Thus, knowledge of E2’s powerful effects on numerous processes can aid in ascertaining 
a more thorough knowledge about the specific mechanisms and consequences of DES 
exposure. 
Enzymatically produced by cholesterol modification, the estrogens are a group of 
steroid hormones that play a critical role in numerous processes of early development. In 
the final step of E2 synthesis, the p450 enzyme aromatase, also termed estradiol synthase, 
aromatizes the A ring of testosterone, thereby generating estradiol (McCarthy, 2008; 
Schug et al., 2011). E2 is often denoted as a gonadal steroid because of its synthesis in 
both the adult ovaries and the brains of neonatal males from androgens originating in the 
developing testes. In addition to this classification, E2 could also be categorized as a 
neurosteroid because all the required enzymes to generate this compound have been 
found in the brain, and some research has shown that it can possibly be synthesized de 
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novo from cholesterol in the brain – specifically in the hippocampus and cortex 
(Amateau, Alt, Stamps, & McCarthy, 2004; McCarthy, 2009).  
The results produced by developmental E2 activity are largely enduring and vary 
extensively. For example, developmental E2 activity is responsible for instituting 
regional sex differences (sexually dimorphic regions) as well as for influencing both 
neurodamaging and neuroprotective effects in the brain. E2 is involved in apoptosis, 
synaptogenesis, and the physical aspects of astrocytes and neurons (e.g., dendritic 
branching). Thus, substantial interest exists regarding how estrogenic EDCs interfere 
with these normal E2 functions (McCarthy, 2008). 
The sexually dimorphic brain. Endogenous steroid hormones, especially E2, are 
vital in the proper sexually dimorphic organization of the brain (Frye et al., 2012; Gore, 
2010). Based on the specific brain region and activity being regulated, sex-based 
differences in the brain are prevalent and vary in power and consequence, with the most 
consistent and profound being related to reproduction. Other sex differences like those 
related to stress, anxiety, locomotion, and cognition are not as robust but are still 
recognized and authentic (McCarthy, 2008).  
Known as the organizational/activational hypothesis of brain sex differentiation, 
steroidal compounds are active during the perinatal sensitive period and determine the 
structure of certain sexually dimorphic brain regions as male or female. Consequently, 
these areas are able to influence sexual behavior in adulthood if the appropriate hormone 
exposure occurs later in life (McCarthy, 2008). Another important notion in research 
regarding development of brain sexual dimorphism is the aromatization hypothesis of 
brain sex differentiation. This theory holds that fetal alpha-fetoprotein (AFP) sequesters 
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maternal E2, and testosterone derived from the testes diffuses to the male brain where 
aromatase converts it to E2. Due to the presence of E2, the course of actions in which 
masculinization of the male brain occurs is then activated. If no E2 reaches the 
developing brain, feminized brain structures will result (i.e., the female morphology is 
considered the default version) (Adewale, Todd, Mickens, & Patisaul, 2011; McCarthy, 
2008). Consequently, early exposure to estrogen-mimicking EDCs like DES, that do not 
bind to AFP, could masculinize the female brain (Adewale et al., 2011), resulting in 
altered brain morphology and behavior. 
Chemicals such as DES with the ability to mimic E2 (and also surpass AFP’s 
protective binding) have obvious potential to disrupt ER expression in numerous areas, 
especially those involved in sexually dimorphic reproductive behavior and physiology. 
Of course it is incredibly important to keep the idea of a critical period of vulnerability in 
mind. It is during this sensitive time that irreversible changes can be elicited. Such a 
concept is undeniably tied to the FEBAD (Fetal Basis of Adult Disease) hypothesis - fetal 
(and neonatal) exposure to estrogenic endocrine-disrupting chemicals is able to 
negatively impact adult health (Patisaul & Adewale, 2009).  
In general, E2’s diverse roles in both the developing and mature brain are far-
reaching. Its influence on various and inter-related aspects of the brain include 
organization of neuronal cells, regulation of numerous signaling pathways, and proper 
differentiation of vital sexually dimorphic regions. It is in this latter function that leads to 
a discussion regarding E2’s effects on emotion-related characteristics – of both animals 
and humans. Anxiety- and depressive-like behaviors are normally divergent in males and 
females. Therefore, disruption of typically dimorphic areas of the brain by estrogenic 
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EDCs such as DES may alter such behavior and contribute to elimination or reversal of 
such sex differences. 
E2 and specific functions of ERs. As previously mentioned, EDCs such as DES 
disturb processes that hormones normally regulate. The mechanisms of these alterations 
are both numerous and complex. Many of these chemicals have the capacity to act 
through several pathways (i.e., both DDE [metabolite of the pesticide DDT] and 
polychlorinated biphenyls [PCBs] display both estrogenic and anti-androgenic properties) 
(Coster & van Larebeke, 2012; Diamanti-Kandarakis et al., 2009).  
To gain a more detailed understanding of how estrogenic EDCs induce 
downstream changes in numerous processes by binding ERs, it is necessary to investigate 
the extensive functions of estrogen and ERs themselves. Normally, upon binding of 
estradiol (E2), ERs dimerize and translocate into the nucleus where they bind to estrogen 
response elements (EREs), encouraging DNA bending and looping and allowing the 
transcriptional machinery to interact with co-regulator proteins. Such proteins include co-
activators, co-repressors, co-integrators, transcription factors, and histone 
acetyltransferases and deacetylases (Lee, Kim, & Choi, 2012). Depending on the 
extracellular proteins and stimuli present, these ER/co-regulator complexes affect the 
transcription of specific target genes in certain organs (Zhao, Dahlman-Wright, & 
Gustafsson, 2008). This activity presents a precise connection between estrogenic 
hormone signals and genetic transcriptional results (Handa, Ogawa, Wang, & Herbison, 
2012).  
To add to these transcriptional regulatory activities, both ERα and ERβ have also 
been found to be involved in rapid, nonclassical estrogen actions in the brain (McEwen & 
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Alves, 1999) wherein ERα and ERβ in the plasma membrane and cytoplasm are involved 
in modulating the phosphorylation of several kinases and other proteins to regulate 
intracellular signaling. Such rapid actions regularly result in the modulation of gene 
expression, and vice versa. This relationship between regulation at the genetic level and 
regulation at the level of rapid intracellular signaling provides a complex picture of 
varied activities for both ERα and ERβ (Handa et al., 2012). When estrogenic EDCs like 
DES bind to these ERs, the consequential cellular and genetic activities may be altered. 
ERα and ERβ have both coinciding and distinctive distribution throughout various 
brain tissues. Both ERs have been found in the preoptic area, bed nucleus of the stria 
terminalis (BNST), medial amygdala, and the periaqueductal grey. Concerning ERα, it is 
more highly expressed in the ventromedial nucleus (VMN) of the hypothalamus and in 
neurons of the arcuate nucleus. Expression of ERβ is more prevalent in the 
suprachiasmatic, supraoptic, and paraventricular hypothalamic nuclei and cerebellum as 
well as the dorsal raphe, hippocampus, and cortex (Handa et al., 2012). Not only are these 
receptors expressed differently in varied areas of the brain, but they also display 
preferential expression in several other tissue types in the body, especially those of the 
reproductive organs. It has been found that ERα is predominant in the uterus, prostate 
stroma, ovarian theca cells, Leydig cells of the testes, epididymis, and breast tissue, as 
well as the liver (Lee et al., 2012). ERβ, however, is more prevalent in the epithelium of 
the prostate, testes, ovarian granulosa cells, and bone marrow (Lee et al., 2012). Such 
differential expression implies that the activities of these ERs are able to independently 
influence several multifaceted functions related to physiology and behavior (Handa et al., 
2012). Studies performed on the brains of adult rodents have found that ERα is more 
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involved in regulating reproduction through its activity in the hypothalamus, while ERβ 
has a more profound effect over non-reproductive activities (Fan, Xu, Warner, & 
Gustafsson, 2010). Therefore, exposure to estrogenic EDCs like DES could lead to 
alterations in ER expression and activity, resulting in modifications of the intricate 
pathways that control such complex functions.  
It is clear that the functions of E2 and ERs are widespread and multifaceted, and 
the focus of much of the EDC literature has been on these estrogenic targets. Interactions 
of EDCs like DES with ERs could potentially alter these functions, resulting in changes 
in both protein expression as well as behavior. 
Influence of E2 on Emotion 
Neurobiological actions of E2 and effects on anxiety and depression. 
Alterations in E2 levels can produce drastic changes in mood and affect, and it is well-
known that estrogens have the ability to affect emotion, especially anxiety (Mora, 
Dussaubat, & Diaz-Veliz, 1996; Tomihara et al., 2009). More specifically, E2 has been 
shown to interact with serotonergic and GABAergic systems to influence such behaviors 
(Krezel, Dupont, Krust, Chambon, & Chapman, 2001; McCarthy, Kaufman, Brooks, 
Pfaff, & Schwartz-Giblin, 1995; Mora et al., 1996; Pandaranandaka, Poonyachoti, & 
Kalandakanond-Thongsong, 2006). It has been established that during the proestrus phase 
of the female estrous cycle, naturally circulating levels of E2 are at their highest, and in 
diestrus, E2 is at its lowest level. This higher level of E2 during proestrus is associated 
with anxiolytic behavior (Marcondes, Miguel, Milo, & Spadari-Bratfisch, 2001; Mora et 
al., 1996). During proestrus, the number of serotonin (5-HT) receptors is significantly 
lower than during diestrus (Biegon, Bercovitz, & Samuel, 1980); this reduction in 
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receptors is accompanied by a decrease in 5-HT in the hypothalamus as well as in the 
limbic and midbrain areas (Kueng, Wirz-Justice, Mensi, & Chappuis-Arndt, 1976). This 
collection of data implies that increased serotonergic activity enhances anxiogenic 
responses; in particular, the decrease in 5-HT activity during proestrus could account for 
lower anxiety levels at this point in the cycle (Marcondes et al., 2001). The potential role 
that E2 could be playing in this scenario relates to its influence on 5-HT receptor density. 
E2 has been reported to decrease 5-HT1 receptors in the rodent brain (Biegon & 
McEwen, 1982). Thus, E2 may be decreasing 5-HT synthesis or receptor density during 
proestrus, resulting in anxiolytic behaviors (Marcondes et al., 2001).  
 Another avenue through which E2 may be affecting anxiety-like behaviors 
involves its ability to affect neuronal excitability (Moss & Gu, 1999). Benzodiazepines 
and similar anxiolytics act on GABA-A receptors to hyperpolarize the post-synaptic 
membrane (Hobbs, Rall, & Verdoon, 1996). It has been reported that progesterone and 
E2 together are able to significantly increase the number of GABA receptors in the brains 
of ovariectomized rats (Maggi & Perez, 1984). Therefore, higher levels of E2 have been 
shown to decrease 5-HT activity, which is associated with anxiolytic behaviors, as well 
as modulate GABA receptors that also induce an attenuation of anxiety (Marcondes et al., 
2001).       
 In addition, the etiology of anxiety and depression disorders has been associated 
with the hippocampus, a crucial brain region involved in the regulation of emotional and 
cognitive responses and where ERβ is highly expressed. Furthermore, previous research 
in both clinical studies as well as animal models has found that E2’s interaction with ERs 
influences the development and function of the hippocampus (Fan et al., 2010). 
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Numerous studies have shown that ERβ may be playing an important role in the 
modulation of anxiety levels (Imwalle, Gustafsson, & Rissman, 2005; Krezel et al., 2001; 
Tomihara et al., 2009). Interestingly, Walf and Frye (2007) showed that these anxiety-
regulating actions of ERβ may be localized to the hippocampus. Rats were microinjected 
with an ERβ selective ER modulator (via guide cannulae) into either the hippocampus or 
the ventral tegmental area [VTA]. When the hippocampus was the target site (compared 
to the VTA control site), rats displayed decreased anxiety behaviors immediately 
following microinjection. Also, administration of a selective ERα modulator into both 
hippocampus and VTA elicited similar effects as microinjection of the control vehicle 
into these sites, suggesting that E2’s anti-anxiety effects likely implicate the actions of 
ERβ, specifically in the hippocampus (Walf & Frye, 2007).  
Studies utilizing ERβ knockout mouse (KO) models have also shown that this 
specific ER may be playing an important role in the modulation of anxiety levels. It has 
been reported that female mice (gonadally-intact) with a disrupted ERβ gene exhibited 
more anxiety-like behaviors than controls (Krezel et al., 2001). In addition, 
ovariectomized ERβ KO mice displayed more anxiety-related behaviors compared to 
wild types (Imwalle, Gustafsson, & Rissman, 2005). Such results imply the involvement 
of ERβ in the anxiety-reducing effects of E2 (Tomihara et al., 2009). 
 The amygdala has also been implicated in emotion, especially in the regulation of 
fear and anxiety responses (LeDoux, 2000). This limbic region has been shown to be 
receptive to treatment with E2. Specifically, administration of E2 was able to increase the 
number of synapses on dendritic shafts in neurons of the amygdala (Nishizuka & Arai, 
1982). In addition, Rasia-Filho, Fabian, Rigoti, and Achaval (2004) reported that during 
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the estrous cycle of rats, when E2 levels are variable, dendritic spine density in the 
medial amygdala also changed. Such results imply that the amygdala is responsive to E2 
and could potentially be involved in E2’s ability to affect emotion-related behavior (Walf 
& Frye, 2006). In rodent models, E2 has been able to alter affective behavior tasks that 
engage the amygdala. Using ovariectomized rats, Walf and Frye (2003) found that 
subcutaneous injection as well as direct intra-amygdala administration (via guide 
cannualae) of E2 augmented stress-induced analgesia after acute exposure to the odor of 
a predator. Furthermore, it has been found that when E2 was administered to the medial 
amygdala, not other control sites, anxiety-like and depressive-like behaviors similar to 
those observed upon systemic dosing of E2 were seen. Specifically, it was reported this 
direct E2 administration resulted in attenuated anxiety-like activity (Frye & Walf, 2004a) 
in addition to decreased depressive-like behavior in the forced swim test (FST) – a 
commonly used measure of depressive behavior (Walf & Frye, 2006). Taken together, 
these data indicate that this region is another probable target of E2 with regard to its 
influence on emotion-related behavior (Walf & Frye, 2006). 
Influence of Developmental Exposure to E2. During fetal life, E2 is a major 
factor in the organization of neural circuitry that manages many different neuroendocrine, 
cognitive, and behavioral functions (Gore, 2010; Gorski, 1985; Palanza et al., 2008). 
Administration of exogenous E2 or ethinyl estradiol (EE2; an estrogenic drug identical to 
E2 with an added ethinyl group) to mothers during pregnancy has been found to produce 
alterations in offspring in not only reproductive and physiological complications (Ryan & 
Vandenbergh, 2006) but also abnormal emotional behaviors (Arabo, Lefebvre, Fermanel, 
& Caston, 2005; Dugard, Tremblay-Leveau, Mellier, & Caston, 2001). The exact 
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mechanism for this is not known, but prenatal exposure to EE2 has been found to affect 
neuronal plasticity (Garcia-Segura, Chowen, Duenas, Torres-Aleman, & Naftolin, 1994) 
particularly neurodevelopment in the cerebral cortex (Siddiqui & Shah, 1997), the 
hypothalamus (Siddiqui & Shah, 1997), and the amygdala (Siddiqui & Shah, 1997).  
Previous research has shown that emotional behaviors have been affected in adult 
rodents exposed to exogenous EE2 during early development. In particular, it has been 
reported that rats whose dams were administered 15 µg/kg EE2 via intraperitoneal 
injections from GD 9 to 14 (a critical time for development of the fetal neural tube and 
gross nervous system structures) displayed increased anxiety-like behavior (Arabo et al., 
2005; Dugard et al., 2001), increased depressive-like behaviors (Arabo et al., 2005), and 
decreased exploratory behavior (Dugard et al., 2001). Another study investigating the 
effects of estrogenic chemicals on behavior found that juvenile rats exposed to 50 µg/L 
EE2 during gestation through puberty exhibited a higher level of anxiety and hesitancy to 
enter the lit chamber in the Light/Dark box (Patisaul et al., 2012). Ryan and Vandenbergh 
(2006) exposed C57Bl/6 mouse dams to 5 µg/kg EE2 via oral gavage from GD 3 to PND 
21 and observed that offspring displayed anxiogenic behavior on the Elevated Plus Maze 
(EPM) and Light/Dark box. Overall these results suggest that developmental exposure to 
EE2 is associated with exhibition of anxiogenic activities and highlights the powerful 
effects that estrogen can have over emotion-related behavior. 
 Adult and peri-menopausal exposure to E2. It has been shown that when E2 
levels are disturbed during adulthood, pronounced alterations in mood and affect can be 
elicited, and it is recognized that estrogen can modify anxiety levels (Tomihara et al., 
2009). Negative symptoms like depression and anxiety that postmenopausal women 
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experience have been correlated with lower levels of estradiol while improved mood has 
been elicited by estrogen replacement therapy (Halbreich, 1997). For example, Sherwin 
and Gelfand (1985) reported that pre-menopausal women who had undergone total 
abdominal hysterectomy (i.e., surgically menopausal) and were treated with either an 
estrogen treatment, an androgen treatment, or a combination estrogen-androgen treatment 
via intramuscular injections had significantly better depression scores (on the Multiple 
Adjective Affective Checklist) compared to a placebo group. Likewise, it was found that 
surgically menopausal women who had been administered intramuscular injections of a 
combination estrogen-androgen treatment or an estrogen treatment reported more positive 
moods than women in the untreated control group (Sherwin, 1988). Whooley, Grady, and 
Cauley (2000) also found that postmenopausal women using estrogen replacement 
therapy at the time of the study had a significantly decreased risk of reporting six or more 
depression symptoms on the Geriatric Depression Scale (GDS) compared to women who 
were not taking estrogen.  In contrast, Saletu et al. (1995) reported that menopausal 
women previously diagnosed with major depression that were given a transdermal 
estradiol treatment for 3 months did not significantly differ from those in the placebo 
group on the Hamilton Depression Rating Scale.  
Numerous studies investigating the effectiveness of treating mood disorders 
associated with hormonal changes have been conducted. Depending upon the specific 
type of treatment, dosing method, duration of treatment, and type of psychological 
assessments used, results have varied. Another possible cause for these inconsistencies 
involves activity of estrogen metabolites like estrone (E1) and estriol (E3), which have 
not been studied as comprehensively as E2 (Watson, Alyea, Cunningham, & Jeng, 2010). 
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However, it is widely accepted that alterations in mood are strongly correlated with 
fluctuations in circulating estradiol, and clinical research is ongoing in regards to the best 
approach to treat such disorders. 
Experimental models using mature rats and mice have also shown that changes in 
emotion-related behaviors were associated with a decreased level of circulating estradiol 
(Tomihara et al., 2009). For example, Estrada-Camarena, Fernandez-Guasti, and Lopez-
Rubalcava (2003) found that administration of E2 and EE2 decreased immobility in the 
FST in adult ovariectomized Wistar rats. Likewise, Rachman, Unnerstall, Pfaff, and 
Cohen (1998) reported that subcutaneous injections of estradiol benzoate in 
ovariectomized Sprague-Dawley rats also induced anti-depressant-like activity in the 
FST. Frye and Walf (2004a) reported that ovariectomized Long-Evans rats 
subcutaneously injected with E2 and Progesterone (P) made more entries into the center 
of the open field and spent more time in the open arms of the EPM compared to the rats 
given only E2, P, or vehicle alone. They also found that when E2, P, or E2 + P was 
directly injected into the medial amygdala via cannulae, the rats exhibited decreased 
anxiety-like behaviors compared to those administered vehicle.  Furthermore, Mora et al. 
(1996) reported that subcutaneous injections of both P and estradiol benzoate in 
ovariectomized Sprague-Dawley rats induced anxiolytic behavior in passive avoidance 
conditioning, but estradiol benzoate antagonized P’s anxiolytic effects on the EPM, 
suggesting that P and E2 may work together to elicit changes in behavior. Another 
example illustrating E2’s anxiolytic influence during adulthood involved behavioral 
testing in Wistar rats on the EPM.  Marcondes et al. (2001) found that females in 
proestrus spent more time in the open arms compared to those in diestrus, when 
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circulating E2 is low. In addition, they reported that there was no difference in behavior 
when E2 was administered to the rats in diestrus. In contrast, another study that used 
adult female Mongolian gerbils reported that chronic oral exposure to EE2 resulted in 
increased social investigation but a decrease in time spent in a novel area and frequency 
of returns to the home cage in a Free Exploratory Test (Razzoli, Valsecchi, & Palanza, 
2005).   
Overall, several factors are apparently at play in E2’s effects on emotional 
behaviors:  dose, dosing duration, and especially the age of exposure (see Table 1 for 
details about effects of developmental and adulthood exposure to estrogen on emotion). 
When estrogen was administered during development, overwhelmingly negative effects 
on anxiety- and depressive-like behaviors in rodents were observed. In contrast, when 
given later in life, estrogen has been shown to impact emotion-related behaviors in a 
more positive way. This stark difference underscores the vulnerability of the developing 
brain and neuroendocrine system and also points to the diverse effects that E2 can 
produce. 
Postpartum Depression and Anxiety 
 Pregnancy, parturition, and nursing are able to provoke changes in the mother’s 
neuroendocrine system; these changes are induced by the developing placenta’s secretion 
of estrogens. When the placenta is lost at birth, a dramatic reduction of estrogens occurs, 
and such oscillation in hormone levels in the mother may affect neuronal function and 
activity (Byrnes, Casey, & Bridges, 2012). These physiological changes in ovarian 
steroids are known to affect behavior and are associated with the onset of postpartum 
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Table 1. Estrogenic effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants 
               
           Sex/ 
                 Age of Exposure/  Species/                              
                                        Exposure Duration/               Strain/ 
Compound        Behavioral Test  Dose        Route of Exposure  OVX’d?     Major Findings        Reference 
 
 
Estradiol    FST           EB 10 µg/.1 ml vehicle       Adulthood/   Female/        ↓ immobility           Rachman et al. 1998   
Benzoate            0 dose control             7 days/     Sprague-Dawley rats     (compared to 0) 
                  S.C. injections  OVX’d 
 
    EPM           P (25 mg/kg) or            Adulthood/  Female/   High light condition  Mora et al., 1996 
         oil first;             1 day/     Sprague-Dawley rats         Oil + EB; P + EB: 
             EB (10 µg/kg; 3 hr. later)    S.C. injection      OVX’d  ↓ % time open arms 
                     or oil         “        “                                  (compared to P + Oil)  
 
   Passive            P (25 mg/kg) or                   Adulthood/   Female/            EB and P:  Mora et al., 1996 
             Avoidance                      oil first;             1 day/     Sprague-Dawley rats      ↓ inhibition of response 
                       EB (10 µg/kg; 3 hr. later)    S.C. injection      OVX’d      (compared to 0) 
            or oil         “        “                                
 
E2  EPM           50 µg/kg                          Adulthood/      Males and Females/                  M = F;                    Marcondes  
                                         1 day/                                    Wistar rats/                   Intact F in Pro.:       et al., 2001 
                  I.P. injection               F intact   ↑ time in open arms   
                                   (compared to Di. F); 
                  Intact F in Pro.:   
                = time in open arms 
                                   (compared to Di. F given E2)   
                
  EPM          E2 (5 µg)              Adulthood/  Female/        E2 + P group:           Frye & Walf, 2004 
                         P (500 µg)               2 days/        Long-Evans rats   ↑ time open arms   
            E2 + P              S.C. injections                OVX’d              (compared to E2, P, 0)  
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           Sex/ 
                 Age of Exposure/  Species/                              
                                        Exposure Duration/               Strain/ 
Compound        Behavioral Test  Dose        Route of Exposure  OVX’d?     Major Findings        Reference 
 
 
  EPM                 E2 (5 µg)              Adulthood/  Female/         E2 + P. E2, P:           Frye & Walf, 2004 
        P (500 µg)               2 days/        Long-Evans rats     ↑ time open arms 
        E2 + P              Cannuala to                 OVX’d                ↑ entries into open arms 
             0 dose control                          amygdala         (compared to 0) 
 
  OFT                     E2 (5 µg)           Adulthood/   Female/         E2 + P group:            Frye & Walf, 2004     
          P (500 µg)                        2 days/        Long-Evans rats ↑ entries into center 
          E2 + P           S.C. injections                OVX’d  (compared to E2, P, 0) 
          0 dose control 
 
  OFT        E2 (5 µg)           Adulthood/   Female/         E2 + P. E2, P:           Frye & Walf, 2004 
          P (500 µg)                        2 days/        Long-Evans rats   ↑ entries into center 
      E2 + P           Cannuala to                  OVX’d               (compared to controls) 
      0 dose control  amygdala 
 
      FST        E2 (2.5-10 µg/rat)          Adulthood/   Female/        ↓ immobility                     Estrada- 
          0 dose control               1 inj. in 2 days/                    Wistar rats/     (compared to 0)                 Camarena 
                     S.C. injections   OVX’d             et al., 2003 
 
EE2  EPM       EE2 (5 µg/kg/day)           GD 3- PND 21/               Female/           ↓ time open arms      Ryan & 
         0 dose control           Oral gavage to dams/         C57-Bl6 Mice/       (compared to 0)        Vandenbergh, 2006 
                 Behav. Testing PND 42          OVX’d 
 
  EPM        EE2 (15 µg/kg/day)               GD 9-14/           Males and Females/      ↑ time closed arms       Dugard et al.,2001 
          0 dose control           I.P. injections to dams/             DA/Han rats/        (compared to 0) 
                 Behav. Testing at     Intact           
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           Sex/ 
                 Age of Exposure/  Species/                              
                                        Exposure Duration/               Strain/ 
Compound        Behavioral Test  Dose        Route of Exposure  OVX’d?     Major Findings        Reference 
 
 
  EPM        EE2 (15 µg/kg/day)               GD 9-14/           Males and Females/      ↑ time closed arms Arabo et al., 2005 
          0 dose control           I.P. injections to dams/             DA/Han rats/      ↓ open arm entries 
                 Behav. Testing at     Intact          (compared to 0) 
                 2.5-3 months of age 
 
     Free Exploration Test       EE2 (15 µg/kg/day)              GD 9-14/           Males and Females/     ↑ latency to enter novel Arabo et al., 2005 
         0 dose control           I.P. injections to dams/             DA/Han rats/  chamber 
                Behav. Testing at      Intact       ↓ time in novel novel 
                2.5-3 months of age     chamber 
            ↓ entries into novel chamber 
                      (compared to 0) 
 
     Free Exploration Test       EE2 (.04 µg/kg/day)           Adulthood/   Females/     ↓ time in novel novel             Razzoli  
         0 dose control           3 weeks/          Mongolian gerbils/               chamber        et al., 2005 
                Oral exposure    Intact  ↓ transitions to home-cage 
                     (compared to 0) 
 
      Light/Dark Chamber      EE2 (5 µg/kg/day)           GD 3- PND 21/               Female/  ↓ time in lighted area       Ryan & 
        0 dose control           Oral gavage to dams/           C57-Bl6 Mice/     (compared to 0)          Vandenbergh, 2006 
                Behav. Testing PND 42         OVX’d 
 
      Light/Dark Chamber      EE2 (1.1 µg/kg/day)            GD 6 – PND 40/       Males and Females/    ↓ % rats to enter Patisaul et al., 
        during gestation;            Dissolved in drinking Wistar rats/      light chamber         2012 
        (1.4 µg/kg/day)            water/     Intact     (compared to 0) 
        during lactation;            Behav. Testing between 
        (around 1.0 µg/kg/day)            PND 24-28 
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           Sex/ 
                 Age of Exposure/  Species/                              
                                        Exposure Duration/               Strain/ 
Compound        Behavioral Test  Dose        Route of Exposure  OVX’d?     Major Findings        Reference 
 
 
              Hole-board      EE2 (15 µg/kg/day)                  GD 9-14/           Males and Females/       ↓ hole pokes            Dugard et al., 2001 
        0 dose control             I.P. injections to dams/             DA/Han rats/     (compared to 0) 
                 Behav. Testing at     Intact 
                 2.5-3 months of age 
 
FST      EE2 (15 µg/kg/day)                 GD 9-14/           Males and Females/         ↑ immobility            Arabo et al., 2005 
        0 dose control            I.P. injections to dams/             DA/Han rats/      (compared to 0) 
                 Behav. Testing at     Intact   
                 2.5-3 months of age         
 
  FST     E2 (2.5-10 µg/rat)         Adulthood/   Female/        ↓ immobility                     Estrada- 
       0 dose control                1 inj. in 2 days/                   Wistar rats/     (compared to 0)                  Camarena 
               S.C. injections   OVX’d             et al., 2003 
 
HRT          MAACL       Climacteron           Adulthood/         Oophorectimized   ↓ depression scores    Sherwin & 
       (Estrogen-Androgen);          3 months on;  women;    (all compared to 0)   Gelfand, 1985 
       Delestrogen           1 month off;   Control: women with  
       (Estrogen);           3 months on                   hysterectomy but  
       Delatestryl           different            intact ovaries 
       (Androgen)           treatment/ 
       Placebo           I.M. injections 
 
          MAACL    Climacteron            Adulthood/         Oophorectimized      E-A and E groups: Sherwin, 1988 
      (Estrogen-Androgen);           1 inj./    women;       ↓ depression scores 
      Delestrogen            I.M. injection    Control: women with        (compared to 0);   
      (Estrogen);            hysterectomy but      No anxiety effects 
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           Sex/ 
                 Age of Exposure/  Species/                              
                                        Exposure Duration/               Strain/ 
Compound        Behavioral Test Dose              Route of Exposure  OVX’d?           Major Findings       Reference 
 
             
             DMRS       Climacteron            Adulthood/         Oophorectimized             E-A group:    Sherwin, 1988 
        (Estrogen-Androgen);            1 inj./    women;        ↓ dysphoric mood 
        Delestrogen            I.M. injection     Control: women with           (compared to E, 0); 
       (Estrogen);            hysterectomy but  E group: 
       Placebo                          intact ovaries       ↓ dysphoric mood 
                      (compared to 0) 
  
             HAMD;  Estraderm TTS            Adulthood/         Menopausal women  = scores  Saletu et al., 1995 
              KI  (50 µg patch)           2 x’s weekly for           diagnosed with           (compared to 0) 
    Placebo            3 months/           major depression 
                Transdermal patch 
 
              GDS  Estrogen therapy                    Adulthood/                       Menopausal women          Current E2 users:               Whooley  
                 Oral or transdermal         classified as either:      ↓ risk of reporting        et al., 2000 
                 Current therapy user           6+ depression 
                  Past therapy user              symptoms 
                  Never therapy user        (compared to past 
          or never users) 
 
Notes. OFT = Open Field Test, EPM = Elevated Plus Maze, FST = Forced Swim Test, HRT = Hormone Replacement Therapy, MAACL = Multiple Adjective 
Affect Checklist, DMRS = Daily Menopausal Rating Scale, HAMD = Hamilton Depression Rating Scale, KI = Kupperman Index, GDS = Geriatric Depression 
Scale, EB = Estradiol Benzoate, E2 = 17β-estradiol, EE2 = Ethinyl Estradiol, P = Progesterone, OVX’d = Ovariectomized, M = Male, F = Female, ↓ decreased, ↑ 




depression (Watson et al., 2010). More specifically, steroid hormones are able to cross 
the blood-brain barrier to directly alter cellular activity and function as well as influence 
neurotransmitter systems that modulate anxiety and depression, thus affecting postpartum 
mood (Lonstein, 2007). 
 The underlying mechanism for the development of postpartum depression (PPD) 
is not fully understood. In the final trimester of pregnancy for humans, it is typical to 
have high levels of estrogen and progesterone as well as a hyperactive hypothalamic-
pituitary-adrenal (HPA) axis leading to elevated plasma cortisol that is also promoted by 
high levels of estrogen and progesterone (Bloch, Daly, & Rubinow, 2003; Nolten, 
Lindheimer, Rueckert, Oparil, & Ehrlich, 1980; Tarantino, Sullivan, & Meltzer-Brody, 
2011). At childbirth and in the beginning of the postpartum period, there is not only a 
steep drop in estrogen and progesterone levels but there is also diminished HPA activity 
because of repressed secretion of hypothalamic corticotrophin-releasing hormone 
(Magiakou et al., 1996). It is known that estrogen and progesterone are able to greatly 
influence the HPA axis and may possibly prompt aberrations in that area in women 
predisposed to anxiety or depression (Tarantino et al., 2011). Furthermore, Bloch et al. 
(2003) has been shown that depressive symptoms were engendered following 
pharmacological withdrawal from E2 and progesterone in women who had previously 
suffered from PPD. It has also been reported that treatment with E2 during the 
postpartum period in women with PPD has resulted in a decrease of depressive symptoms 
(Ahokas, Kaukoranta, & Aito, 1999; Ahokas, Kaukoranta, Wahlbeck, & Aito, 2001).  
 To examine potential mechanisms for PPD, experimental studies utilizing animal 
models have used a hormone-simulated pregnancy (HSP) regimen (Navarre, Laggart, & 
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Craft, 2010). In this HSP model, daily hormone injections are administered to simulate 
the hormone levels achieved during pregnancy. Following termination of the injections, 
the female rodents are tested for depressive-like behaviors, typically on the Forced Swim 
Test. These studies have shown that the withdrawal of E2 following HSP led to increased 
immobility in this test (i.e., more depression-like behavior) compared to control animals 
(Galea, Wide, & Barr, 2001; Stoffel & Craft, 2004). In addition, Molina-Hernandez and 
Tellez-Alcantara (2001) have reported that rats (previously pregnant and still gonadally 
intact) displayed more depressive-like behavior in the Forced Swim Test during the early 
postpartum period compared to rats in mid-pregnancy. Such results suggest that E2 
withdrawal is most likely one of the primary factors in the etiology of PPD. One 
proposed reason for this association between the reduction in E2 and depressive 
symptoms implicates the disturbance of serotonergic and/or noradrenergic 
neurotransmission. As stated previously, it is known that E2 is able to downregulate 
certain 5-HT receptors, and it has also been found to upregulate tryptophan hydroxylase, 
the enzyme necessary for the conversion of tryptophan into 5-HT (Navarre et al., 2010; 
Pecins-Thompson, Brown, Kohama, & Bethea, 1996; Rubinow, Schmidt, & Roca, 1998). 
Therefore, it seems possible that exposure to an EDC like DES during pregnancy could 
influence E2’s normal postpartum effects in the brain and result in an exacerbation of any 
abnormalities that might occur following childbirth. 
 Concerning postpartum anxiety, there are several hypotheses speculating its 
etiology. Most women actually experience a reduction in anxiety after childbirth, and 
parturient rodents typically exhibit anxiolytic behaviors (Lonstein, 2007). However, PPD 
is commonly associated with peripartum anxiety in women (Barnett & Parker, 1986), and 
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this type of anxiety is a strong predictor of PPD (Bergant, Heim, Ulmer, & Illmensee, 
1999). One theory regarding the precipitation of postpartum anxiety involves abnormal 
fluctuation of prolactin (PRL) and oxytocin (OT) during the peripartum period, and 
higher levels of these hormones are associated with reduced anxiety (Lonstein, 2007). It 
is thought that abnormal activity of hypothalamic PRL- and OT-synthesizing neurons 
projecting to numerous brain areas may be potentially involved in the regulation of 
anxiety following childbirth (Lonstein, 2007; Paut-Pagano, Roky, Valatx, Kitahama, & 
Jouvet, 1993; Sofroniew, 1980). In addition, one factor that has received much attention 
regarding its possible role in affecting postpartum anxiety is activity of the HPA axis. As 
previously stated, the HPA axis is suppressed during late pregnancy (de Weerth & 
Buitelaar, 2005). It is thought that the lack of continued suppression during the 
postpartum period may result in hyperarousal and anxiety (Lonstein, 2007; Tsigos & 
Chrousos, 2002). Even more hyperarousal may be elicited because of a reduction in the 
usual anxiolytic effects of ovarian steroids, which could be due to such high HPA 
activation (Walf & Frye, 2005).   
Estrogens, progestins, and other neurosteriods are known to radically oscillate 
during the peripartum period. These hormones enter the brain and may affect postpartum 
mood indirectly by altering activity of serotonergic, dopaminergic, and GABAergic 
neurotransmitter systems that can modulate anxiety (Andrade, Nakamuta, Avanzi & 
Graeff, 2005; Birzniece et al., 2006; Pandaranandaka et al., 2006). However, there is not 
much support for the hypothesis that ovarian hormones play a significant role in the 
production of persistent postpartum anxiety (Lonstein, 2007). It has been shown, though, 
that plasma, hippocampal, and cortical levels of alloprenanolone, a reduced metabolite of 
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progesterone that also acts as a positive allosteric regulator of the GABA-A receptor, falls 
significantly within 3 days following parturition in rats (Concas, Follesa, Barbaccia, 
Purdy, & Biggio, 1999; Frye & Walf, 2004b). Furthermore, in women, alloprenanolone 
levels also stay quite low for at least 6 months after childbirth (Epperson et al., 2006). 
Perhaps this abrupt reduction in neurosteroids and resulting inactivity in the activation of 
the GABA-A receptor could produce an upsurge in neural excitability and anxiety 
(Lonstein, 2007). 
Reported Effects of DES on Emotion  
Due to the influence on emotion-based behaviors that alterations in E2 and/or ERs 
can elicit, it is clear that estrogenic EDCs could potentially change the downstream 
signaling cascades that are responsible for producing the numerous gene and protein 
products affecting hormone levels and brain morphology that eventually contribute to the 
final endpoint – altered behavior. Recall that DES was administered to pregnant women 
beginning in the 1930s and into the early 1970s to prevent miscarriage and pregnancy-
related difficulties. It has been speculated that this estrogenic compound may also be able 
to influence the brain, behavior, and resulting psychological conditions (Vessey et al., 
1983). As with other estrogenic endocrine disruptors, DES does not bind to AFP, thus 
allowing it to reach the fetal brain to induce changes in E2 and ER-regulated activities 
that are able to affect anxiety- and depressive-like behavior in humans and animals. It has 
been reported that DES-exposed women have an amplified proportion of depression, 
anorexia, and learning disabilities (O’Reilly et al., 2010; Vessey et al., 1983).    
An extensive literature search resulted in several studies examining the 
prospective link between developmental exposure to DES and depression symptoms. The 
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main focus of most of these papers is concerning psychiatric illness in adult women that 
were subjected to DES in utero. However, some studies do describe psychological 
effects, or the absence thereof, in exposed men as well.  
 Early developmental exposure. Numerous epidemiological investigations have 
examined the incidence of psychological disorders with a primary emphasis on the 
occurrence of major depressive disorder (MDD) in adult men and women exposed to 
DES in utero. Contradictory results have been reported. Because of the nature of the 
studies (varied questionnaires and criteria used for diagnosis, sample sizes, methods of 
collecting data), interpretation is difficult (Kebir & Krebs, 2012). Vessey et al. (1983) 
was the first to report higher rates of depression and anxiety disorders in DES sons and 
daughters. However, in the Vessey study, a questionnaire was sent in the mail to general 
practitioners of the participants and the results were not centered on standardized criteria 
for diagnoses and were not based on structured interviews with patients. Several other 
studies have utilized small samples (maximum 50 participants in each group) and 
evaluated the presence of psychiatric illness by using semi-structured interviews and 
standardized criteria (Ehrhardt et al., 1987; Fried-Cassorla, Scholl, Borow, Strassman, & 
Bowers, 1987; Meyer-Bahlburg et al., 1985; Pillard et al., 1993). Due to the possible 
confound of distress over either actually having or likely developing reproductive 
problems, a clinical control group (i.e., women with abnormal Papanicolaou test results) 
was included in some studies (Ehrhardt et al., 1987; Fried-Cassorla et al., 1987). 
Specifically, Ehrhardt et al. (1987) reported that lifetime rates of MDD were significantly 
higher in the DES group compared to general population norms; however, differences 
between the DES group and the clinical control Papanicolaou (PAP) group were not 
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significant. Two of the small sample studies that did not use a clinical control group 
found that DES-exposed men had a significantly higher incidence of MDD during their 
lifetimes compared to non-exposed control men (Meyer-Bahlburg et al., 1985; Pillard et 
al., 1993).  
One study used a large cohort (from the National Cancer Institute) of male and 
female participants who had been exposed to DES in utero but only asked women about 
issues with mental illness. Titus-Ernstoff et al. (2003) found no differences in the 
frequency of depression, anxiety, psychosis, or eating disorders between the DES cohort 
and unexposed sisters and age-matched controls. The data was collected through a self-
report questionnaire. Because no standardized criteria or structured interview was 
utilized, there is a chance that women suffering from a serious psychiatric illness may not 
have participated. This possibility would suggest a potential under-representation of the 
real prevalence of psychiatric problems in this cohort (Kebir & Krebs, 2012; Titus-
Ernstoff et al., 2003). 
Two more recent studies using large subsamples from general population cohorts 
have reported opposing results. Verdoux, Ropers, Costagliola, Clavel-Chapelon, and 
Paoletti (2007) surveyed mothers (all participating in a French general population survey) 
using self-report questionnaires sent through the mail. The mothers gave information on 
psychiatric illness on DES-exposed children as well as unexposed siblings, and results 
showed no differences between the groups. In contrast, O’Reilly et al. (2010) used a 
cohort from the Nurses’ Health Study II, a group of over 116,000 American female 
nurses born between 1946 and 1965 and who have completed a questionnaire about their 
lifestyle and any newly diagnosed diseases every two years since 1989. Participants who 
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had confirmed exposure to DES completed self-report questionnaires that asked about 
history of depression and use of antidepressant medication. It was shown that exposed 
women reported a higher incidence of depression (having depression symptoms and use 
of antidepressant medication) compared to women who were not exposed.  
Only two published papers report results of developmental exposure to DES and 
behavioral tests of emotional behavior using animal models. Kubo et al. (2003) found 
that DES abolished sex differences observed in control rats in the measure of time spent 
in the center of the arena in the OFT. In particular, it was reported that both males and 
females in the DES group spent more time in the center, an anxiolytic behavior, 
compared to controls. One study investigated the effects of developmental DES exposure 
on both wild-type and ERα knockout C57Bl/6J mice. They reported that the mice 
prenatally exposed to DES from GD 11 to 17 exhibited anxiety-like behavior in the OFT 
as adults, regardless of genotype. However, in the Light-dark transition test, prenatal DES 
exposure resulted in elimination of sex differences in the wild-type mice while no DES 
effects were observed in either male or female ERαKO mice, suggesting that DES exerts 
its influence by binding to ERα (Tomihara et al., 2006). 
Kaitsuka et al. (2007) also examined prenatal DES exposure in male mice but 
used the passive avoidance test as a measure of learning and memory. They reported that 
mice in the DES-exposed group entered the dark chamber (previously associated with 
foot shock) significantly more after an acquisition period compared to control animals; 
such results suggest a more anxiolytic state and impaired memory in the exposed mice.  
 Adulthood exposure. Regarding exposure to DES during adulthood in animal 
models, there is only one published study that discusses measures of depressive-like 
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behavior. Estrada-Camarena et al. (2003) investigated the effects of DES (in addition to 
E2 and EE2) administration in adult ovariectomized rats and reported no differences 
following DES exposure on behavior in the FST. However, only one subcutaneous 
injection of the estrogenic compound was given 48 hours prior to behavioral testing. A 
schedule of chronic exposure in an adult animal model would be more informative. There 
are no reports of major depression or other psychiatric conditions in the mothers who 
were given DES during their pregnancies (see Table 2 for details about effects of 
developmental and adulthood exposure to DES on emotion). 
 Neurobiological mechanisms of DES exposure. The precise mechanisms by 
which DES could be eliciting emotion-related behavioral alterations are yet to be 
determined. As stated earlier, ERα seems to be the ER subtype most affected by DES. 
Furthermore, E2 actions in the hippocampus may also play an important role in 
regulating emotion. Prenatal DES exposure in mice has been shown to result in altered 
passive avoidance responses in male offspring as well as increases in pCaMKII activity 
and expression, a kinase that plays a noteworthy role in promoting long term potentiation 
(LTP) in the hippocampus (Kaitsuka et al., 2007; Soeda, Tanaka, Shirasaki, & Takahama, 
2010). Interestingly, this altered passive avoidance response and kinase activity was 
significantly mitigated in mice prenatally exposed to DES but reared in an enriched 
environment (Soeda et al., 2010). Perhaps DES’s ability to disrupt normal hippocampal 
signaling activity affecting LTP could similarly influence surrounding signaling 
molecules and expression of certain proteins that may also elicit varied outcomes with 
regard to regulation of emotion.   
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Table 2. Diethylstilbestrol effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants 
                
 
           Sex/ 
              Age of Exposure/  Species/                              
                                     Exposure Duration/               Strain/ 
                     Behavioral Test  Dose     Route of Exposure  OVX’d?          Major Findings     Reference 
 
 
     OFT   6.5 µg/kg/day GD 0 – PND 21/         Males and Females/         ↑ time in center Kubo et al., 2003 
     0 dose control Drinking water to dams/  Wistar rats/          (compared to 0) 
       Behav. Testing PND 42    Intact             DES M = F 
                              (compared to 0 M ≠ F) 
 
     OFT   0.1 µg/animal GD 11- 17         Males and Females/        ↓ time in center   Tomihara et al., 
     0 dose control Oral exposure to dams/           C57Bl/6J mice/         (compared to 0;          2006 
       Behav. Testing PND 35            some ERαKO;            regardless of  





    Light/Dark Chamber  0.1 µg/animal GD 11- 17         Males and Females/                   WT F:    Tomihara et al., 
     0 dose control Oral exposure to dams/           C57Bl/6J mice/         ↓ time in light side            2006 
       Behav. Testing PND 35            some ERαKO;             (compared to 0 WT F);  
           Some WT                  WT M: 
                            ↑ time in light side 
                                          (compared to 0 WT M); 
                               DES WT M = F: 
                              time in light side 
                             (compared to 0 WT M ≠ F)  
 
                     Passive Avoidance  0.1 µg/animal GD 11- 17                  Males/  ↑ entries into lit chamber        Kaitsuka 
                  Test   0 dose control Oral exposure to dams/             DDY mice         (compared to 0)      et al., 2007 







Table 2. Diethylstilbestrol effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants 
    
  
                        Sex/ 
              Age of Exposure/  Species/                              
                                     Exposure Duration/               Strain/ 
                     Behavioral Test  Dose     Route of Exposure  OVX’d?            Major Findings       Reference 
 
   
Passive Avoidance  0.1 µg/animal GD 11- 17                  Males/         DES non-enriched:              Soeda 
Test   0 dose control Oral exposure to dams/             ddyY mice   ↑ entries into lit chamber      et al., 2010 
     Behav. Testing at 6 weeks/   (compared to DES enriched; 
     Some raised in enriched environ.    0 enriched) 
   
FST   .25-1 mg/rat       Adulthood/   Females/       No significant effects          Estrada- 
     0 dose control 1 inj. in 2 days/                      Wistar rats/      Camarena et al., 
       S.C. injections                   OVX’d                 2003 
 
              General Practitioner 
      Questionnaire   DES tablets Gestation           Male and Female/           ↑ incidence of         Vessey et al.,  
     (5 mg/day) (starting around       Children of women in       anxiety and depression              1983 
     Placebo   6h week of pregnancy)/        University College    in both sons and daughters 
       Oral exposure to mothers/            Hospital Trial       (compared to placebo) 
       Mean age of exposed             (randomized, 
       Subjects = 23-29 years     double-blind controlled  
                    trial of DES for  
                      first pregnancy)  
in the 1950s/ 
                      Reported by 
                General Practitioners 
 
           SADS-L/RDC  DES exposure Gestation (variable times)/          Women exposed         ↑ rates of MDD in      Ehrhardt et al.,  
     No exposure Mothers given tablets/       in utero compared to              both groups;             1987 
       Mean age of exposed   age-matched controls with          DES = control 
       Subjects = 25 years       abnormal Pap smears/  
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           Sex/ 
              Age of Exposure/  Species/                              
                                     Exposure Duration/               Strain/ 
                     Behavioral Test  Dose     Route of Exposure  OVX’d?             Major Findings       Reference 
 
    
      SADS-L/RDC  DES exposure Gestation (variable times)/       Men exposed in utero         ↑ rates of MDD in   Meyer-Bahlburg  
     No exposure Mothers given tablets          compared to men               both groups;      & Ehrhardt, 
           with minor urological issues        DES = control          1987 
            and men possibly exposed/ 
                        Clinic sample 
        
     SADS-L/RDC                DES exposure Gestation (variable times)/      Men exposed in utero           ↑ rates of MDD   Meyer-Bahlburg 
     No exposure Mothers given tablets       compared to normal      (compared to controls)       & Ehrhardt, 
                            unexposed men/              1985 
                    Clinic sample 
 
      SADS-L/RDC  DES exposure Gestation (variable times)/      Men exposed in utero            ↑ rates of MDD         Pillard et al., 
     No exposure Mothers given tablets       compared to normal             (compared to  1993 
                                      unexposed brothers/          unexposed brothers); 
                    Clinic sample     = rates lifetime depression, 
                    alcoholism, and current  
                     psychiatric symptoms 
                         (compared to 
                                general population)   
  
       DIS/DSM III   DES exposure Gestation (variable times)/        Women exposed            ↑ rates of MDD      Fried-Cassorla 
     No exposure Mothers given tablets     in utero compared to              (compared to  et al.,  
             unexposed sisters and          unexposed sisters);  1987 
             women with abnormal      = rates of MDD between 
                    Pap smears/        abnormal Pap group 
                   Clinic sample           and DES group 
 




Table 2. Diethylstilbestrol effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants 
                
           Sex/ 
              Age of Exposure/  Species/                              
                                     Exposure Duration/               Strain/ 
                     Behavioral Test  Dose     Route of Exposure  OVX’d?             Major Findings           Reference 
 
 
              Questionnaire  DES exposure Gestation (variable times)/       Women exposed      No significant differences         Titus-  
     No exposure Mothers given tablets/     in utero compared to             between groups      Ernstoff et al.,  
       Most subjects were    unexposed sisters and               2003 
       older than 35 years    age-matched controls/ 
            combination of 4 DES 
                 cohorts from the  
           National Cancer Institute         
       
       Questionnaire  DES exposure Gestation (variable times)/       Women exposed      No significant differences        Verdoux 
     No exposure Mothers given tablets/     in utero compared to             between groups            et al., 2007 
       Mean age of subjects       unexposed sisters/ 
       = 36 years  Subgroup of E3N cohort 
          (general population cohort 
            of mothers surveyed for 
               cancer risk factors)       
 
       Questionnaire  DES exposure Gestation (variable times)/       Women exposed        ↑ history of depression             O’Reilly 
     No exposure Mothers given tablets/     in utero compared to        (compared to controls)          et al., 2010 
       Mean age of subjects       unexposed women/ 
       = 39 years      Subgroup of Nurses’ 
            Health Study II Cohort 
 
 
Notes. OFT = Open Field Test, FST = Forced Swim Test, SADS-L/RDC = Schedule for Affective Disorders and Schizophrenia-Lifetime version/Research 
diagnostic criteria, DIS/DSM III = Diagnostic Interview Schedule/Diagnostic and Statistical Manual III, DES = Diethylstilbestrol, M = Male, F = Female, ↓ 
decreased, ↑ increased, = equal to, ≠ no difference 
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In addition, Mize, Poisner, and Alper (2001) reported that E2 and DES (when 
independently administered) were able to act via ERs to reduce 5-HT(1A) receptor 
function in the hippocampus and frontal cortex in an in vitro assay using brain samples 
from adult ovariectomized rats. This finding agrees with the results of Marcondes et al.  
(2001) and Biegon and McEwen (1982) regarding E2’s ability to reduce 5-HT receptor 
expression, dependent upon the level of circulating E2 available. Therefore, DES, like 
E2, could modify 5-HT receptor expression in adults to also elicit changes in emotion-
related behaviors. 
Rationale and Hypotheses of the Current Study  
With the diversity of results in the epidemiological data regarding psychological 
health following developmental exposure to DES, there is not a clear consensus regarding 
the potential of this estrogenic EDC to be a causative factor in the etiology of anxiety and 
depression. A possible and very powerful confound in this research is the knowledge of 
exposure and/or problems with reproductive function, and epidemiological research has 
not been able to distinctly tease out the specific cause for the higher reported rates of 
emotion-related problems in women exposed to DES in utero. The experimental studies 
that have used a developmental dosing paradigm have reported similar anxiety-like 
behaviors that were observed following exposure to E2 and bisphenol A (BPA), also an 
estrogenic endocrine disruptor (Cox, Gatewood, Howeth, & Rissman, 2010; Gioiosa, 
Fissore, Ghirardelli, Parmigiani, & Palanza, 2007; Gioiosa, Parmigiani, vom Saal, & 
Palanza, 2013; Kubo et al., 2001; 2003; Palanza et al., 2008; Patisaul et al., 2012). 
Furthermore, due to estrogen’s ability to influence emotion in adult humans and mature 
animals, particularly during and after pregnancy, it is also necessary to assess behavioral 
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alterations following DES administration in pregnant adult rodents. It is also known that 
there is substantial comorbidity between depression and anxiety disorders (Hirschfeld, 
2001). Therefore, the present study intended to investigate the possible emotion-related 
behavioral ramifications (measuring both anxiety- and depressive-like behaviors) of 
developmental exposure as well as exposure during pregnancy. It was hypothesized that 
prenatal DES exposure would result in increased anxiety- and depression-related 
behaviors in female offspring. Because the mental health problems have been more 
prevalent in DES daughters than DES sons, this project focused on only the female 
offspring.  In addition, it was predicted that dams exposed to DES would exhibit altered 
emotion-related behavior. 
Though it has not been prescribed for human use in several decades, investigation 
into DES is still quite relevant. Because of its potential to induce transgenerational 
genetic modifications that may make it more likely that the children and grandchildren of 
the original prenatally exposed generation might develop complications later in life 
(Newbold, 2011), more information is needed regarding the effects of this compound on 
emotional regulation. Furthermore, due to its similarity to other estrogenic endocrine 
disruptors, being able to extrapolate from previous research regarding developmental 
exposure and the possible influence it could have on the etiology of psychiatric illness 
could be quite telling concerning questions about early exposure to estrogenic EDCs and 




Chapter 2:  Methods 
Subjects 
Eighty female and 40 male C57Bl/6 mice (5-6 weeks of age) were obtained from 
Harlan Laboratories and the females were identified by ear punch upon arrival. All mice 
were maintained in a temperature- and humidity-controlled room (22 degrees Celsius, 40-
55% humidity) on a 12:12 hour regular light-dark cycle (on at 0700, off at 1900).  
Females were double-housed in a standard polysulfone shoebox cage (inspected and 
determined to be free of wear) with wood chip bedding. A standard low soy diet (Harlan 
2020X) and reverse osmosis filtered water in glass bottles were available ad libitum. 
After one week of acclimation, a breeder male (previously single-housed) was introduced 
into the cage with the two females. Starting the following morning, females were checked 
daily for the presence of a vaginal plug. If present, the female was moved to her own 
cage and that day denoted as gestational day (GD) 0. Females that did not show signs of a 
vaginal plug or other signs of pregnancy after seven days were re-paired with a different 
breeder male. All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Memphis and were in accordance with the 
Public Health Service Policy on Humane Care and Use of Laboratory Animals (National 
Institutes of Health [NIH], 2002) and the Guidelines for the Care and Use of Mammals in 
Neuroscience and Behavioral Research (National Research Council [NRC], 2003).   
Exposure 
The female mice were randomly assigned to exposure groups and given one of 
four treatments consisting of either DES (0.1, 1.0, or 10.0 µg/kg) (Sigma-Aldrich) or the 
control vehicle (tocopherol-stripped corn oil only).  Dams were orally gavaged daily 
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starting on GD 11 and continuing until GD 17. The appropriate volume of each dose 
(typically in the range of 35 - 50 µl, depending on the dam’s weight) was loaded into the 
flexible tip of a positive displacement pipette and administered to the dam via oral 
gavage. The current study’s planned dosing duration was selected to encompass a critical 
time of central nervous system (CNS) development in mice (beginning in late prenatal 
life) when estrogen irreversibly organizes brain circuitry in a sex-dependent manner. In 
addition, these doses and this timeline were chosen according to other studies that have 
examined behavior in prenatally-exposed mice (Kaitsuka et al., 2007; Soeda et al., 2010; 
Tomihara et al., 2006). Furthermore, the current study’s proposed doses of DES have 
been shown to not elicit any gross physical abnormalities (Fielden, Fong, Haslam, & 
Zacharewski, 2002; Fielden et al., 2002), but doses in this range have resulted in altered 
behaviors (for examples, see Table 2). 
Procedure 
 Births/weaning and reproductive/developmental endpoints. Three days 
following parturition (PND 3), all the pups were sexed, weighed, and examined for any 
abnormalities. Any incidence of stillbirth was also recorded. The litters were culled to six 
to seven pups (retaining as many females as possible) using cervical dislocation to 
euthanize extra pups. In order to increase the size of small litters and to guarantee that 
each litter contained at least six to seven pups, extra pups from the same treatment group 
were cross-fostered if available. Cross-fostered pups were marked by ear clip and did not 
undergo behavioral testing. Successful litters were obtained from 9, 12, 8, and 10 dams 
who received the 0, 0.1, 1.0, or 10.0 µg/kg doses, respectively. However, one dam in the 
1.0 DES group had only one female. Because preference was given to the OVEX 
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condition, this female was ovariectomized but did not survive the surgery, resulting in n 
= 7 for female offspring in this exposure group. 
Postnatal weight gain was monitored in the pups weekly until weaning on PND 
21. Anogenital distance was measured on PND 21 for all pups. On the day of weaning, 
each litter’s dam was separated. The dam was re-housed with other dams from the same 
treatment group. From each litter, three females were retained for behavioral testing and 
were housed in the same cage until surgery. The remaining pups in each litter were 
euthanized at weaning via overexposure to CO2, trunk blood collected, and weights of the 
brain and liver acquired from one male and one female per litter (when available). Brain 
samples were frozen and stored for later analyses. 
 Ovariectomies. Two days after weaning, dams underwent ovariectomy surgery. 
In addition, one-third of the female offspring (on approximately PND 60) also underwent 
this surgery. Each mouse was first placed into an induction box containing isofluorane 
until adequate anesthesia was obtained at which point they were quickly removed. An 
anesthetized animal was placed in lateral recumbency and positioned to breathe into a 
nose cone delivering 2-3% isofluorane. Surgery was performed using aseptic methods as 
much as possible. Bilateral ovariectomies were performed. The target area was shaved 
and betadine antiseptic solution and then 70% alcohol were applied. A .5 cm lateral 
incision was made that was about 1 – 1.5 cm caudal to the 13th rib. The fascia was 
cleared away using blunt dissection and the underlying muscle wall cut with a scissors. 
Forceps were used to locate the fat pad containing an ovary which was extracted through 
the incision. A cauterizer was used to remove the ovary. The uterine horn was then 
placed back into the body cavity, the muscle wall closed with suture, and the skin 
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incision closed with a single stainless steel staple (which was removed 5 to 7 days later).  
The same protocol was used for mice that received the SHAM surgery, with the 
exception that the ovaries were not removed. 
To prevent infection and to reduce pain, subcutaneous injections of baytril and 
carprofen (doses based on each animal’s weight) were administered while mice were still 
under anesthesia. The anesthesia was then discontinued and mice continuously monitored 
until awake and alert enough to move about on forelimbs. Mice were then placed in an 
individual cage and observed in the main laboratory until fully awake.  Upon regaining 
consciousness, each animal was returned to its colony room in the U of M Animal 
Vivarium  and monitored. Mice were given subcutaneous injections of baytril and 
carprofen for two days following surgery. Post-surgical weights were collected daily and 
all mice monitored for signs of distress or infection for one week following surgery.  
The mice were then given two weeks to recover (also allowing for complete 
reduction in circulating estrogen) before undergoing behavioral testing. For each litter, 
one female offspring had the ovaries removed (i.e., OVEX female), one female had a 
sham surgery wherein the procedure was the same as an ovariectomy with the exception 
that the ovaries were not removed (i.e., SHAM female), and the final retained female did 
not have surgery (i.e., INTACT female). 
 Behavioral testing. The dams and all mice retained after weaning underwent all 
behavioral tests. The order of testing for all subjects was: Elevated Zero Maze, Open 
Field Test, Tail Suspension Test, and Forced Swim Test. There were at least two days 
between each testing session. 
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Anxiety-related behaviors:  Two behavioral tests designed to examine anxiety-
related behaviors in mice were conducted on all retained female offspring. The first 
anxiety behavioral test was the Elevated Zero Maze which is one of the most commonly 
used behavioral measures of anxiety (Kulkarni, Singh, & Bishnoi, 2007). Anxiogenic 
behavior is associated with time spent in the closed quadrants, while anxiolytic behavior 
is associated with time spent in the open quadrants. Testing lasted for 5 min. The testing 
apparatus consisted of a ZeroMaze Digital Monitoring System (AccuScan Instruments, 
Inc., Colombus, OH). The test chamber was a black circular platform and consisted of 
open and closed quadrants elevated 108.9 cm off the floor with a platform measuring 5 
cm in width. The closed quadrants were enclosed by clear acrylic walls (28.5 cm in 
height). The diameter of the maze was approximately 40 cm (inner diameter = 30 cm). 
The closed quadrants were equipped with eight light beams that transmitted the amount 
of time spent in and activity in the closed quadrants. The open quadrants had a slightly 
raised Plexiglas lip to prevent mice from slipping off the maze.  Each mouse was placed 
in closed Quadrant 1 of the maze to begin the test (see Cook, Williams, & Flaherty, 
2001).  A thorough cleaning of the maze with ethanol occurred between each subject. The 
dependent measures collected included latency to enter an open quadrant, percent time 
spent in open and closed quadrants, percent time spent each of the four quadrants, and 
activity in closed quadrants.  
The next anxiety test for each subject was the Open Field Test (OFT), which has 
been used extensively in the literature as a behavioral measure of anxiety (Choleris, 
Thomas, Kavaliers, & Prato, 2001).  In the OFT, anxiety is quantified based on how 
much time the animal spends in the center versus the periphery of the testing chamber. 
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Time spent near the periphery is indicative of an anxiogenic state (increased anxiety) 
while time in the center of the arena suggests an anxiolytic state (decreased anxiety). The 
OFT chamber consisted of a square plastic arena (46.5 x 46.5 x 46.5 cm) bisected with 
photobeams and equipped with a video-tracking system. Each mouse was placed in the 
center of the arena and allowed to move freely for 10 min. The entire chamber was 
placed in a testing cubicle equipped with a fan to buffer extraneous noise.  Dependent 
measures included time spent in the center area, the number of entries into the center 
area, the number of photobeam breaks in the center area, number of photobeam breaks in 
the periphery, duration of time spent frozen, number of rears, and duration of rears.  
Depression-related behaviors:  Two measures of depressive-like behavior were 
collected in all of the subjects. The tail suspension test (TST) has been extensively used 
to measure depressive-behavior in mice and has the advantage of controlling for 
locomotor confounds (Cryan, Mombereau, & Vassout, 2005).  For this test, immobility 
while suspended is likened to hopelessness and giving up which are significant 
characteristics of depression (Cryan et al., 2005). The TST apparatus (Kinder Scientific; 
San Diego, CA) consisted of a cubicle furnished with a strain gauge which is a hook 
linked to a vertical bar that digitally detected mobility.  The mouse was suspended by its 
tail with tape from the strain gauge for 6 min.  The total duration of immobility was the 
dependent measure and was computed as the total time the subject’s movement is below 
a pre-determined threshold.  Specifically, immobility was characterized as the lack of any 
initiated movements and included passive swaying.   
The second depressive measure was the forced swim test (FST). The FST 
apparatus (Kinder Scientific; San Diego, CA) consisted of a clear Plexiglas or glass 
43 
 
cylinder (height = 61 cm; diameter = 29 cm) filled with fresh tap water up to the level of 
50 cm.  The FST protocol used has been previously described (Castagne, Porsolt, & 
Moser, 2009; Ferguson, Cisneros, Hanig, & Berry, 2007). Briefly, each mouse was 
placed in the water-filled cylinder (temperature ~ 25°C) for 6 min.  Afterwards, the 
subject was removed, towel dried, allowed to rest in a cage on a heating pad, and then 
returned to its home cage.  The testing apparatus was emptied, rinsed, and refilled with 
fresh water after each subject’s test session to eliminate any pheromone effects. The 
duration immobility or floating (making only those movements absolutely necessary to 
keep the head above water) was measured. Also, the number of climb/struggle 
movements (making lively movements with forepaws, usually against the cylinder wall), 
and swim distance (making swimming motions, more than needed to keep the head above 





Chapter 3:  Data Analysis 
All statistical analyses were conducted using SPSS for MS Windows (version 
22.0, SPSS Inc.; Chicago, IL) with statistical significance set at p < 0.05. 
Reproductive/Developmental Endpoints 
Dams. Gestational weight gain for the dams was analyzed with a one-way 
between subjects ANOVA (DES exposure group was the between-subjects factor). 
Offspring. The data analysis for developmental outcomes including postnatal 
weight gain and anogenital distance was essentially the same. For these dependent 
variables, the mean value for males and females within each litter was calculated and 
analyzed with a mixed 4 (DES exposure) x 2 (sex) repeated-measures ANOVA, where 
DES exposure was the between-subjects factor, and sex was nested within litter. Because 
litters were small and most pups were retained for behavioral testing, there were not 
many full sets of male and female littermates sacrificed at weaning. Therefore, for brain: 
body weight ratio and liver: body weight ratio, these variables were analyzed with a one-
way between-subjects ANOVA separately for males and females. 
Behavioral Tests  
Dams. The data analysis for each anxiety- and depression-related behavior was 
essentially the same. Each dependent variable was analyzed with a one-way between 
subjects ANOVA (DES exposure group was the between-subjects factor). Quadrant (for 
the EZM) and one-minute block (for the EZM, OFT, TST, and TST) were also included 
as repeated-measures factors when appropriate. When significant exposure-related effects 
were obtained from the overall analyses, additional Dunnett post hoc analyses were 
conducted to determine which exposure groups differed from the control group.  
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Female offspring.  In instances where fewer than 3 female pups/litter were 
available, assignment to the OVEX group was given priority. Missing littermate data was 
determined by using the mean for the other females in the same DES exposure and 
surgery group.  To ensure that this did not dramatically alter the experimental results, any 
dependent variable that required mean substitution was analyzed both with the substituted 
mean and also by dropping the entire litter from the analysis. In all cases, mean 
substitution did not change the overall pattern of results.  
The data analysis for each anxiety- and depression-related behavior was 
essentially the same. Each dependent variable was analyzed with a 4 (Exposure) x 3 
(Surgery) mixed ANOVA. As the three female offspring (OVEX, SHAM, INTACT) 
were all from the same dam, this variable was a repeated-measures factor (i.e., nested 
within litter). Quadrant (for the EZM) and one-minute block (for the EZM, OFT, TST, 
and TST) were also included as repeated-measures factors when appropriate. When 
significant exposure or surgery main effects were obtained from the overall analyses, 
additional Dunnett or simple contrast post hoc analyses were conducted to determine the 




Chapter 4:  Results 
 For the sake of brevity, only dependent variables that revealed significant effects 
involving exposure for the dams will be discussed. For the female offspring, only 
dependent variables that revealed statistical significance for exposure- or surgery-related 
effects will be discussed. 
Reproductive/Developmental Endpoints 
Dams. The effects of DES exposure on gestational weight gain are presented in 
Figure 1. There was no significant effect of DES on gestational weight gain in the dams. 
Offspring. The effects of DES exposure on postnatal weight gain and anogenital 
distance (AGD) are shown in Figures 2 and 3, respectively. The effects of exposure on 
brain: body weight (BW) ratio and liver: BW ratio are presented in Table 3. For postnatal 
weight gain, there was a significant Exposure x Day [F(9, 102) = 1.988, p = .048] and 
Sex x Day [F(3,32) = 4.294, p = 0.12] interaction. There was also a significant main 
effect of sex [F(1,34) = 5.940, p = .020] for postnatal weight gain where males weighed 
significantly more than females. Further post hoc simple contrasts conducted within each 
sex revealed that were no significant exposure-related differences on any day. There were 
no exposure-related effects for AGD; however, there was an expected significant effect 
of sex [F(1, 34) = 637.156, p < .001] where males had larger AGDs than females (see 
Figure 3). Finally, there were no significant effects of exposure found for brain: BW or 






Table 3. DES Offspring Brain:Body Weight and Liver:Body Weight Ratios  
 




0 µg/kg/day  
 MALE (n=4)         .039 ± .002       .048 ± .003 
 FEMALE (n=5)         .041 ± .003       .046 ± .002  
  
0.1 µg/kg/day  
 MALE (n=4)         .040 ± .001       .045 ± .004 
 FEMALE (n=7)         .043 ± .001       .047 ± .004   
1.0 µg/kg/day  
 MALE (n=5)         .039 ± .001       .050 ± .002 
 FEMALE (n=2)         .043 ± .008       .047 ± .008  
   
10.0 µg/kg/day  
 MALE (n=4)         .039 ± .001       .048 ± .002 
 FEMALE (n=1)         .046        .041  
Note. Means (± SEM); n = # of weanling samples  









Figure 2. Postnatal weight gain for male offspring (top panel) and female offspring 




Figure 3. Anogenital distance (AGD) for male and female DES offspring on PND 21. Males had significantly larger AGDs than 
females.        
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 Elevated zero maze. The effects of DES exposure on the latency to enter the open 
quadrant, percent time in open quadrants, open quadrant entries, and activity counts in 
closed quadrants for the dams are presented in Table 4. No significant effects of exposure 
were found on any of the dependent variables analyzed for the EZM. 
 Open field test. The effects of DES exposure on the percent time in the center, 
number of center entries, percent time freezing, and percent time rearing for the dams are 
presented in Table 5. No significant effects of exposure were found on any of the 
dependent variables analyzed for the OFT.   
Depression measures. 
 Tail suspension test. The effects of DES exposure on immobility time for the 
dams are presented in Table 6. No exposure-related effects were found in the analysis for 
immobility time in the TST. 
 Forced swim test. The effects of DES exposure on immobility time, basic 
movements/struggle, and swim distance for the dams are presented in Table 7. No 




 Elevated zero maze. The effects of DES exposure and surgical status on the 
latency to enter the open quadrant, percent time in open quadrants, open quadrant entries, 
and activity counts in closed quadrants are presented in Table 8. Only one significant 
exposure-related effect was found in the analyses for the EZM. For the variable of entries 
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Table 4. Elevated Zero Maze Results Following Gestational DES Exposure in Dams  
 
 DES Dose   Latency to             Percent Time                     Open     Closed  
GD 11 - 17   Enter Open       in Open                 Quadrant       Quadrant 
    Quadrant    Quadrants                    Entries    Activity 
    (Seconds)             (Breaks/ 




0 µg/kg/day (n=9)  11.30 ± 4.73    13.38 ± 3.59                54.56 ± 17.17              1.60 ± 0.12 
              
   
0.1 µg/kg/day (n=11)     5.62 ± 1.58   11.68 ± 1.98               59.55 ± 11.06              1.59 ± 0.09 
    
   
1.0 µg/kg/day (n=8)     4.51 ± 1.92   15.14 ± 2.52               79.50 ± 10.92              1.89 ± 0.16 
   
   
10.0 µg/kg/day (n=10)    4.55 ± 2.01   13.46 ± 4.00               60.20 ± 15.78              1.96 ± 0.22 
    
Note. Means (± SEM); n = # of successful litters.  




Table 5. Open Field Test Results Following Gestational DES Exposure in Dams  
 
 DES Dose   Percent Time   Number of             Percent Time             Percent Time 




0 µg/kg/day (n=9)   4.76 ± 1.32   17.33 ± 3.93    76.80 ± 2.15   9.11 ± 1.33 
   
  
0.1 µg/kg/day (n=11)    6.62 ± 1.98    15.73 ± 2.89   79.50 ± 1.26   7.86 ± 0.73 
   
 
1.0 µg/kg/day (n=8)    5.65 ± 1.79    18.13 ± 4.09   77.11 ± 1.78             10.85 ± 2.16 
   
  
10.0 µg/kg/day (n=10)   5.33 ± 1.10   20.40 ± 4.27   74.98 ± 2.60    7.66 ± 0.74 
      
Note. Means (± SEM); n = # of successful litters.  




Table 6. Tail Suspension Test Results Following Gestational DES Exposure in Dams  
 




0 µg/kg/day (n=9)     258.89 ± 15.53 
  
 
0.1 µg/kg/day (n=10)      230.91 ±  9.99 
           
 
1.0 µg/kg/day (n=8)      226.80 ± 13.44 
           
 
10.0 µg/kg/day (n=10)     229.28 ± 17.21   
    
Note. Means (± SEM); n = # of successful litters.  






Table 7. Forced Swim Test Results Following Gestational DES Exposure in Dams  
 
 DES Dose               Time        Basic      Swim    
GD 11 - 17                Immobile (sec)                        Movements            Distance (cm)    
      
 
0 µg/kg/day (n=9)         138.57 ± 10.16           934.33 ± 47.47            513.78 ± 23.71 
           
   
0.1 µg/kg/day (n=11)           147.00 ±   6.97            921.36 ± 31.14           512.27 ± 14.75 
              
   
1.0 µg/kg/day (n=8)           132.60 ±  8.58            977.88 ± 31.14           537.25 ± 15.05 
                
   
10.0 µg/kg/day (n=10)          145.17 ±  8.32           936.70 ± 39.41           508.10 ± 20.57   
         
Note. Means (± SEM); n = # of successful litters.  





Table 8. Elevated Zero Maze Results Following Gestational DES Exposure in Female Mice  
 
 DES Dose   Latency to             Percent Time                     Open     Closed  
GD 11 - 17   Enter Open       in Open                 Quadrant       Quadrant 
    Quadrant    Quadrants                    Entries    Activity 
    (Seconds)             (Breaks/ 
                    Second) 
 
 
0 µg/kg/day (n=9) 
 OVEX     3.09 ± 4.60    22.70 ± 4.60      76.67 ±   5.78  1.91 ± 0.14 
 SHAM   13.23 ± 3.47   17.12 ± 2.92     93.44 ± 14.42   2.24 ± 0.15 
 INTACT    2.48 ± 2.19   20.47 ± 3.79      91.22 ± 17.69  1.92 ± 0.23 
 
0.1 µg/kg/day (n=12)  
 OVEX   11.21 ± 3.14   20.56 ± 3.77   102.50 ± 15.23  2.07 ± 0.12 
 SHAM     4.91 ± 3.01   20.43 ± 2.63   102.42 ±   8.66  2.10 ± 0.14 
 INTACT  10.33 ± 1.90   20.82 ± 3.53     80.83 ±   7.24  2.14 ± 0.17 
 
1.0 µg/kg/day (n=7)  
 OVEX     3.54 ± 4.11   15.64 ± 4.73     80.86 ± 17.69  1.85 ± 0.19 
 SHAM     9.95 ± 3.94   21.52 ± 4.21   105.14 ± 12.67  2.21 ± 0.18 
 INTACT    1.45 ± 2.49   22.92 ± 5.24     75.00 ± 12.28  1.63 ± 0.24 
 
10.0 µg/kg/day (n=10)  
 OVEX     5.89 ± 3.43   13.39 ± 3.35     82.50 ± 11.40  1.83 ± 0.08 
 SHAM   10.31 ± 3.30   18.22 ± 3.71     94.10 ±   8.43  1.95 ± 0.11 
 INTACT    5.30 ± 2.08   24.87 ± 3.79   101.70 ± 10.65  2.25 ± 0.09 
 
Note. Means (± SEM); n = # of successful litters.  
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into closed quadrants, there was a significant Exposure x Surgery x Quadrant interaction, 
F(6,68) = 2.447, p = .033. Within each quadrant, further post hoc Dunnett tests revealed 
that there were no significant exposure differences within any surgery group. Additional 
post hoc simple contrasts found no significant surgery effects within any exposure group 
(Figure 4).  
While few DES exposure-related effects occured, several surgery-related effects 
were found. A significant main effect of surgery was found for latency to enter an open 
quadrant, F(2,33) = 3.334, p = .048. However, further post hoc simple contrasts revealed 
no significant differences among the surgery groups (Figure 5). There was a significant 
Surgery x Block interaction for entries into the open quadrants [F(8,27) = 2.646, p = 
.028] and for entries into closed quadrants [F(8, 27) = 2.780, p = .022]. As can be seen in 
Figure 6, in block 2, OVEX mice made significantly fewer entries into the open and 
closed quadrants compared to the SHAM mice (p = .018 and .016, respectively). No other 
surgery-related differences were found in any other block for either of these variables. 
 Open field test. The effects of DES exposure and surgical status on the percent 
time in the center, number of center entries, percent time freezing, and percent time 
rearing are presented in Table 9. No significant effects of exposure were found on any of 
the dependent variables analyzed for the OFT, with the exception of percent time rearing, 
for which there was a significant Exposure x Surgery x Block interaction, F(54,57) = 
1.676, p = .028. Further post hoc analyses of the significant Exposure x Surgery x Block 
interaction on percent time rearing revealed that in the OVEX group, the control group 
spent significantly more time rearing compared to 0.1 DES group in both block 2 (p = 
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Table 9. Open Field Test Results Following Gestational DES Exposure in Female Mice  
 
 DES Dose   Percent Time   Number of   Percent Time   Percent Time 
GD 11 - 17        Center            Center Entries       Freezing        Rearing 
 
 
0 µg/kg/day (n=9) 
 OVEX   11.66 ± 1.89   27.89 ± 3.90    71.13 ± 1.54   14.87 ± 1.16 
 SHAM     9.77 ± 1.64   28.11 ± 3.45   69.45 ± 1.94   12.37 ± 1.45 
 INTACT  20.79 ± 3.61   39.00 ± 5.38   66.21 ± 1.64   14.23 ± 2.00 
 
0.1 µg/kg/day (n=12)  
 OVEX   10.37 ± 2.27    27.50 ± 2.66   69.82 ± 1.75   10.38 ± 0.65 
 SHAM     9.83 ± 1.72    26.67 ± 3.19   70.04 ± 1.55    10.67 ± 1.21 
 INTACT  16.41 ± 2.12   33.17 ± 3.13   66.15 ± 1.71   13.99 ± 1.23 
 
1.0 µg/kg/day (n=7)  
 OVEX     9.24 ± 1.20    28.00 ± 2.10   70.56 ± 1.19    12.93 ± 1.19 
 SHAM   10.13 ± 2.33   30.57 ± 6.02   66.74 ± 2.26    11.39 ± 1.16 
 INTACT  12.00 ± 2.44    34.00 ± 5.50   69.15 ± 2.11   10.42 ± 1.91 
 
10.0 µg/kg/day (n=10)  
 OVEX   11.22 ± 2.92   23.20 ± 4.00   72.18 ± 1.94   12.96 ± 1.36 
 SHAM   12.54 ± 2.35   29.00 ± 3.97   70.07 ± 1.64   15.10 ± 1.80 
 INTACT  13.27 ± 0.76   33.00 ± 2.71   67.40 ± 0.32   11.97 ± 0.97 
Note. Means (± SEM); n = # of successful litters.  





Figure 4. Elevated Zero Maze:  Entries into closed quadrants for female offspring.  
Initial = Closed quadrant in which the mice were first placed. Opposite: Closed quadrant 









Figure 6. Elevated Zero Maze:  Entries into the open and closed quadrants for the female 
offspring. A = OVEX group made significantly fewer entries compared to SHAM and 
INTACT groups into the open and closed quadrants.     
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.031) and in block 4 (p = .008), while there were no significant exposure effects in any of 
the testing blocks within the SHAM or INTACT groups (Figure 7).  
While few DES exposure-related effects were found, several surgery-related 
effects were determined. A significant main effect of surgery was found for percent time 
in the center [F(2, 33) = 6.589, p = .004], entries into the center [F(2,33) = 6.205, p = 
.005], center activity counts [F(2,33) = 5.254, p = .010], peripheral activity counts 
[F(2,33) = 6.395, p = .004], center vertical counts (rears) [F(2,33) = 5.813, p = .007], and 
percent time frozen [F(2,33) = 7.726, p = .002]. Additional post hoc analyses revealed the 
INTACT mice a) spent significantly more time in the center compared to the SHAM (p = 
.001) and the OVEX (p = .004) mice (Figure 8), b) made more entries into the center area 
compared to the SHAM (p = .007) and OVEX (p = .002) mice (Figure 9), c) had 
significantly more activity counts (or photobeam breaks) in the center area than the 
SHAM (p = .041) and OVEX (p = .001) mice (Figure 10), d) made significantly more 
activity counts (or photobeam breaks) in the periphery than the OVEX (p < .001) mice 
(Figure 11), e) made significantly more vertical counts in the center area compared to the 
SHAM (p = .002) and OVEX (p = .002) mice (Figure 12), and f) spent significantly less 
time frozen than the OVEX (p < .001) mice (Figure 13).  
There was also a significant Surgery x Block interaction on the percent time spent 
in the center, F(18,17) = 3.237, p = .010. As can be seen in Figure 8, in blocks 1, 8, 9, 
and 10 INTACT mice spent more time in the center area than the OVEX mice (p = .012, 
.005, .021, and .006, respectively). A significant difference was observed between the 





Figure 7. Open Field Test:  Percent time spent rearing for female offspring.  
Top graph:  OVEX group only; A = Control group spent significantly more time rearing 
than the 0.1 DES group in these blocks. No other exposure effects were observed for this 




Figure 8. Open Field Test:  Percent time spent in the center of the chamber for the female offspring. Below:  INTACT group spent 
significantly more time in center than the SHAM and OVEX groups. Inset:  Percent time in center by block. A = INTACT group spent 
more time in center compared to SHAM and OVEX groups during this block; B = INTACT group spent more time in center than the 





Figure 9. Open Field Test:  Entries into center of the chamber for the female offspring. INTACT group made significantly more 




Figure 10. Open Field Test:  Activity counts (beam breaks) in the center of the chamber for the female offspring. The INTACT group 




Figure 11. Open Field Test:  Activity counts (beam breaks) in the periphery of the chamber for the female offspring. The INTACT 




Figure 12. Open Field Test:  Vertical counts (rears) in the center of the chamber for female offspring. The INTACT group made 






Figure 13. Open Field Test:  Percent time spent frozen for the female offspring. The OVEX group spent significantly more time 
frozen compared to the INTACT group.      
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As indicated above, the three-way interaction of Exposure x Surgery x Block for 
percent time rearing was also significant, F(54,57) = 1.676, p = .028. Within each block, 
the effect of surgery within each level of exposure was also examined. For the 0 DES 
group, the OVEX mice were significantly different from the SHAM mice (p = .015) in 
block 2 while in block 4 the OVEX mice and INTACT mice spent significantly more 
time rearing compared to the SHAM mice (p = .001 and .032, respectively). For the 0.1 
DES group, INTACT mice spent more time rearing than the OVEX mice in blocks 6, 7, 
8, and 10 ( p = .012, .025, .006, and p = .024, respectively). The INTACT mice also spent 
more time rearing than the SHAM mice in blocks 6 and 10 (p = .003 and .018, 
respectively). No significant Surgery differences were found in the 1.0 or 10.0 DES 
groups (see Figure 7).  
Depression measures. 
 Tail suspension test. The effects of DES exposure and surgical status on 
immobility time are presented in Table 10. No exposure-related effects were found in the 
analysis for immobility time in the TST. There was a significant Surgery x Block 
interaction for time spent immobile, F(10,25) = 3.620, p = .004. Within-subjects simple 
contrasts post hoc analysis within each block revealed significant surgery group 
differences only within block 6. Specifically, the INTACT mice spent significantly more 
time immobile compared to SHAM (p = .037) and OVEX (p = .014) mice (see Figure 
14). No significant surgery differences were revealed in the other testing blocks. 
 Forced swim test. The effects of DES exposure and surgical status on immobility 
time, basic movements/struggle, and swim distance are presented in Table 11. No 
exposure-related effects on time spent immobile on the FST were found. However, for 
71 
 
Table 10. Tail Suspension Test Results Following Gestational DES Exposure in 
Female Mice  
 




0 µg/kg/day (n=9) 
 OVEX        192.22 ± 16.16 
SHAM      199.90 ± 12.46 
INTACT     219.31 ± 11.37 
 
0.1 µg/kg/day (n=12)  
 OVEX        193.53 ± 14.22   
SHAM      194.68 ± 13.19  
INTACT     206.22 ±   7.76 
 
1.0 µg/kg/day (n=7)  
 OVEX        186.35 ± 13.88   
SHAM      191.31 ± 16.36  
INTACT     217.10 ± 13.54 
 
10.0 µg/kg/day (n=10)  
 OVEX        191.95 ± 20.84   
SHAM      203.82 ±  7.61  
INTACT     198.06 ±  9.68 
 
Note. Means (± SEM); n = # of successful litters.  
DES = Diethylstilbestrol, OVEX = ovariectomy surgery, SHAM = sham surgery, 




Table 11. Forced Swim Test Results Following Gestational DES Exposure in Female Mice  
 
 DES Dose               Time        Basic      Swim    
GD 11 - 17                Immobile (sec)                        Movements            Distance (cm)   
       
 
0 µg/kg/day (n=9) 
 OVEX          161.60 ± 13.56           829.11 ± 32.02            457.78 ± 30.08    
 SHAM            189.92 ± 12.69           818.22 ± 65.08           406.44 ± 34.45    
 INTACT         198.74 ± 10.59           826.00 ± 22.09           404.00 ± 19.04    
 
0.1 µg/kg/day (n=12)  
 OVEX          164.70 ± 11.94            877.67 ± 34.98           481.25 ± 25.47    
 SHAM          194.47 ±   7.08            861.25 ± 35.68           411.00 ± 15.47     
 INTACT         177.89 ±   8.09           905.83 ± 36.00           433.88 ± 17.08    
 
1.0 µg/kg/day (n=7)  
 OVEX           178.91 ±   6.66            814.57 ± 34.07           445.00 ± 20.90     
 SHAM          191.05 ±   7.22           874.57 ± 54.07           421.00 ± 18.66     
 INTACT         167.20 ± 12.12            911.29 ± 48.41           451.33 ± 19.37    
 
10.0 µg/kg/day (n=10)  
 OVEX           177.24 ±   7.68           832.80 ± 23.36           447.40 ± 15.98    
 SHAM           189.68 ± 12.28           843.00 ± 35.89           403.63 ± 24.52    
 INTACT          181.71 ±   7.64           817.90 ± 35.45           407.86 ± 14.71    
Note. Means (± SEM); n = # of successful litters; sec = seconds, cm = centimeters.  





Figure 14.  Tail Suspension Test:  Time immobile for female offspring. A = INTACT group spent significantly more time immobile 
compared to the SHAM and OVEX groups in this block.   
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basic movements/struggle there was a significant Exposure x Block interaction, F(15, 96) 
= 1.878, p = .035, and a significant Exposure x Surgery x Block interaction, F(30,81) = 
1.244, p = .011. The effect of exposure at each block and within each level of surgery 
revealed that in the OVEX group, the 0 DES group made significantly fewer struggle 
movements than the 0.1 DES group (p = .041) in block 2. In the INTACT mice, the 0 
DES group made significantly fewer struggle movements compared to the 0.1 DES (p = 
.038) and 1.0 DES (p = .009) mice in block 5. There were no significant exposure effects 
in any blocks in the SHAM mice (see Figure 15). 
For swim distance there was also a significant Exposure x Block interaction, 
F(15, 96) = 2.096, p = .016, and a significant Exposure x Surgery x Block interaction, 
F(30, 81) = 1.897, p = .012. Post hoc simple effects analyses (collapsed across surgery) 
revealed no significant effects of exposure within any individual testing block. 
Considering each surgical group separately, the effect of exposure at each block within 
the INTACT group revealed the 0 DES group had a significantly shorter swim distance 
compared to the 0.1 DES (p = .045), the 1.0 DES (p = .020), and the 10.0 DES (p = .044) 
groups in block 4 and the 1.0 DES group (p = .010) in block 5. There were no significant 
exposure effects in any blocks within the OVEX or SHAM groups (see Figure 16).  
 There was a significant main effect of surgery on time immobile, F(2, 33) = 
4.535, p = .018, and swim distance, F(2,33) = 6.125, p = .005. The OVEX mice spent 
significantly less time immobile compared to the SHAM mice (p = .002; Figure 17) and 
had a greater swim distance compared to the SHAM (p < .001) and INTACT (p = .027) 
mice (see Figure 18). There was also a significant Surgery x Block interaction on time 




Figure 15. Forced Swim Test:  Basic movements/struggle for female offspring.  
Top graph:  OVEX group only; A = Control group made significantly fewer basic 
movements compared to the 0.1 DES group in this block. Bottom graph:  INTACT group 
only; B = Control group made significantly fewer basic movements compared to the 0.1 
and 1.0 DES groups in this block. No exposure effects were observed in the SHAM 




Figure 16. Forced Swim Test:  Swim distance for female offspring (Exposure effect).  
Bottom graph:  INTACT group only; A = Control group had significantly shorter swim 
distance than 0.1, 1.0, and 10.0 DES groups in this block; B = Control group had 
significantly shorter swim distance than 1.0 DES group in this block. No exposure effects 




Figure 17. Forced Swim Test: Time immobile for female offspring. Below: SHAM group spent significantly more time immobile than 
the OVEX group. Inset:  A = SHAM group spent significantly more time immobile than the OVEX and INTACT groups in these 




Figure 18.  Forced Swim Test:  Swim distance for female offspring (Surgery effect). Below: OVEX group had significantly greater 
swim distance compared to the SHAM and INTACT groups. Inset:  A = SHAM group had significantly shorter swim distance than 
OVEX group in this block; B = SHAM group had significantly shorter swim distance than INTACT and OVEX groups in this block.   
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can be seen in Figure 17 (inset), in blocks 3 and 4 (respectively) the SHAM mice spent 
significantly more time immobile compared to the OVEX (p = .003, p = .002) and the 
INTACT (p = .034, p = .003) mice. Likewise, in block 3, SHAM mice had a significantly 
shorter swim distance than OVEX mice (p < .001), while in block 4, the SHAM mice had 
a significantly shorter swim distance compared to the INTACT (p = .018) and OVEX (p 
= .003) mice (see Figure 18 inset).  
As previously mentioned, a significant Exposure x Surgery x Block interaction 
was also found for basic movements, F(30, 81) = 1.897, p = .012 and swim distance, 
F(30, 81) = 1.897, p = .012.  For basic movements (see Figure 15), no significant surgery 
differences were found within any blocks for the 0 dose DES group. For the 0.1 DES 
group, it was revealed that in block 2, the OVEX mice made significantly more basic 
movements compared to the SHAM mice (p = .008) while in block 4, the INTACT mice 
made significantly more basic movements compared to the OVEX mice (p = .017). For 
the 1.0 DES group, it was shown that in block 6, the INTACT mice made significantly 
more basic movements than the OVEX mice (p = .005). Finally, for the 10.0 DES group, 
the SHAM mice made significantly more basic movements compared to the INTACT 
mice (p = .012) in block 6. For swim distance, no significant surgery differences were 
found in any blocks for the control or 1.0 DES groups but this was not the case for the 0.1 
and 10 DES groups (see Figure 16). For the 0.1 DES group, it was revealed that the 
SHAM mice had a significantly shorter swim distance compared to the OVEX mice in 
block 2 (p = .011) and block 4 (p = .011). For the 10.0 DES group, it was found that the 
INTACT mice had significantly shorter swim distance compared to the SHAM (p = .043) 
and OVEX mice (p = .013) in block 1, while in block 2 the SHAM mice had a 
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significantly shorter swim distance compared to the INTACT (p = .003) and OVEX (p = 
.022) mice.   
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Chapter 5:  Discussion 
Summary of Results and Relation to Previous Literature 
 The overall results for this study revealed that exposure to varying doses of DES 
during late pregnancy did not exert a robust, systematic influence over anxiety- and 
depressive-like behaviors in C57Bl/6 dams or female offspring. Several effects of the 
surgery manipulation were found in the female offspring, especially for anxiety-like 
measures in the OFT and depressive-like measures on the FST.  In general, on the OFT, 
the INTACT group displayed less anxiety-like behaviors compared to the other surgery 
groups, while on the FST, OVEX mice spent less time immobile and exhibited a greater 
swim distance. 
There were no significant exposure-related effects in any of the behavioral tests 
for the dams. As previously stated, only a handful of experimental studies examining 
DES exposure and its potential effects on tests of emotionality in rodents have been 
published. There are no reports about the possible influence of adulthood DES exposure 
on anxiety-like behavior; however, Estrada-Camarena et al. (2003) showed that a single 
subcutaneous injection of DES in ovariectomized Wistar rats 48 hours before testing in 
the FST did not elicit any significant behavioral alterations. Likewise, the present study 
found no effects of DES exposure in ovariectomized mouse dams on any of the 
behavioral measures, even after a more chronic schedule of exposure. These results imply 
that DES exposure during late pregnancy does not impact the etiology of postpartum 
depression or anxiety. 
Concerning the female offspring in the current study, the only significant 
exposure-related effect in the tests of anxiety was for percent time spent rearing in the 
OFT, wherein the control OVEX mice spent more time rearing (an exploratory behavior) 
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compared to the 0.1 DES OVEX mice in minutes 2 and 4 of the testing session. This 
subtle DES-related finding was not robust enough to suggest that anxiety-like behavior 
was significantly altered by exposure alone.  
There have been inconsistent reports about the possible effects of developmental 
exposure to DES on anxiety in rodents, and only two of these studies have included an 
examination of the potential influence of DES in female offspring. For example, Kubo et 
al. (2003) showed that intact male and female Wistar rats exposed to 6.5 µg/kg/day DES 
from GD 0 to PND 21 via drinking water given to the dams resulted in an increase in 
center time in the OFT, a decrease in anxiety-like behavior, on approximately PND 42. In 
contrast, Tomihara et al. (2006) orally dosed C57Bl/6J mouse dams heterozygous for 
ERαKO with 0.1 µg DES or control vehicle from GD 11 to 17. Behavioral testing 
occurred around PND 35 in both ERαKO and wild type intact male and female offspring. 
Regardless of genotype, DES-exposed males and females displayed more anxiogenic 
behavior in the OFT compared to control animals. Tomihara et al. (2006) also showed 
that wild type DES-exposed females were more anxious in the Light/Dark Chamber, 
while the wild type DES-exposed males displayed anxiolytic behavior; those results were 
consistent with other findings that have reported a reversal of sex differences following 
developmental exposure to estrogenic compounds in tests of anxiety-like behavior in 
rodents (Farabollini, Porrini, & Dessi-Fulgheri, 1999; Fujimoto, Kubo, & Aou, 2006; 
Gioiosa et al., 2013; Kubo et al., 2001; Palanza et al., 2008).  
There are some critical methodological aspects to consider when comparing the 
present investigation with these two studies. The current study controlled for any type of 
excess exposure to other estrogenic compounds during development (i.e., non-
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polycarbonate plastic cages, filtered water in glass water bottles, low-soy rodent chow). 
Both the Kubo et al. (2003) and Tomihara et al. (2006) studies did not utilize such 
controls. Other substantial differences between the current study and the report from 
Kubo et al. (2003) are in regard to the rodent species used (Wistar rats versus C57Bl/6 
mice) as well as the duration of DES exposure (GD 0 to PND 21 versus GD 11 to 17). 
Further, mice in the Tomihara et al. (2006) study were tested during their dark cycle 
while mice in the present study were tested during the light cycle. In addition, the current 
study conducted behavioral testing in adult offspring to examine potential emotion-
related effects caused by developmental DES exposure that could persist later in life. In 
contrast, both Kubo et al. (2003) and Tomihara et al. (2006) conducted behavioral tests in 
intact animals that had not yet reached adulthood (PND 42 and PND 35, respectively), 
and unexposed adolescent rodents have been shown to perform differently from their 
adult counterparts on tests of emotionality (Adriani & Laviola, 2004). For example, it has 
been shown that C57Bl/6J mice in periadolescence displayed more anxiety-like behavior 
in the OFT compared to adults (Hefner & Holmes, 2007).  
With regard to alterations in depressive-like behaviors following developmental 
exposure to DES, there are no published reports. In the present study, no exposure-related 
effects were found for time spent immobile in either the TST or FST, the primary 
measure of behavioral despair in these assays. However, there were significant DES 
effects for both basic movements/struggle and swim distance in the FST. In the OVEX 
group, control mice struggled less than the 0.1 DES mice in minute 2 of the test. Also, it 
was shown that within the INTACT mice, controls made fewer struggle movements 
compared to the 0.1 and 1.0 DES groups in block 5 only. Both of these results show that 
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for both the OVEX (i.e., no circulating E2) and the INTACT (i.e., circulating E2) groups, 
control mice with no DES exposure actually displayed more behavioral despair in these 
select testing blocks. For swim distance, it was shown that INTACT controls swam less 
than all DES groups in block 4 and that the controls also had significantly shorter swim 
distance than the 0.1 DES group in block 5 of the testing session, suggesting that the 
INTACT control mice displayed more behavioral despair compared to the INTACT 
DES-exposed mice in these specific blocks of time. These findings, however, did not 
illustrate a strong, systematic effect of DES exposure, suggesting that early 
developmental exposure to this potent estrogenic compound does not lead to significant 
alterations in depressive-like behavior in either of these tests of behavioral despair during 
adulthood.     
Many epidemiological studies examining the incidence of emotion-related 
disorders in the human population that was exposed to DES in utero have been published. 
While several of these investigations have reported significant differences in 
psychological problems, specifically increased rates of anxiety and depression-related 
disorders (Meyer-Bahlburg et al., 1985; O’Reilly et al., 2010; Pillard et al., 1993; Vessey 
et al., 1983), others have reported no such discrepancies between DES-exposed women 
and control groups (Ehrhardt et al., 1987; Fried-Cassorla et al., 1987; Titus-Ernstoff et 
al., 2003; Verdoux et al., 2007). In the careful consideration of these epidemiological 
studies, one critical and very possible confound has been present - was the increased 
incidence of psychological disorders in DES-exposed women due to this estrogenic 
compound altering development and organization of the brain and central nervous 
system, or was it due to other environmental factors (i.e., knowledge of increased risk of 
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cancer, stress and concern regarding other aspects of gynecological health such as 
abnormal reproductive organs and infertility) (Fried-Cassorla et al., 1987; Kebir & Krebs, 
2012)?   
To attempt to control for this confound, two studies have employed clinical 
control groups in their analysis of rates of psychiatric disorders and symptoms. For 
example, Ehrhardt et al. (1987) included a clinical control group that consisted of women 
with abnormal Papanicolaou smears (abnormal PAP group) in the same age range and of 
similar socioeconomic status compared to the DES-exposed group. The authors 
suggested that the inclusion of this particular clinical control group was appropriate, 
because both the DES-exposed women and the abnormal PAP women would have 
undergone similar medical procedures in addition to having higher risk of reproductive 
health problems and increased rates of genital cancer. To summarize, Ehrhardt et al. 
(1987) reported that the DES-exposed women and the abnormal PAP women had 
significantly increased rates for anxiety and depression symptomatology on the SCL-90-
R (a self-report assessment) in comparison to population norms, but the two groups did 
not significantly differ from each other. Likewise, Fried-Cassorla et al. (1987) also 
included an abnormal PAP clinical control group in addition to a control group that 
consisted of unexposed sisters of women in the DES group. Using the DIS/DSM III (a 
highly structured interview to assess psychiatric illness diagnoses), these authors reported 
that both the DES-exposed women and the abnormal PAP women had significantly 
increased incidence of major depression compared to the unexposed sister controls; 
however the DES group and the abnormal PAP group were not different from each other 
in the rate of this diagnosis (Fried-Cassorla et al., 1987).  
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A more recent epidemiological study using a large cohort (from the National 
Cancer Institute) asked DES-exposed women about issues with psychiatric illness using a 
self-report questionnaire; no differences in the frequency of depression, anxiety, 
psychosis, or eating disorders between the DES cohort and unexposed sisters and age-
matched controls were found (Titus-Ernstoff et al., 2003). Furthermore, Verdoux et al. 
(2007) surveyed mothers (all participating in a French general population survey) using 
self-report questionnaires. The mothers provided information on psychiatric outcomes for 
DES-exposed children as well as unexposed siblings, and results revealed that there were 
no differences between the groups.  
In agreement with the current study’s experimental results, these epidemiological 
findings suggest that it was not DES exposure alone that resulted in increased rates of 
psychiatric illness including anxiety and depression disorders. However, it is more likely 
that the elevated risk of developing such symptomatology is associated with patients’ 
current environmental stressors, such as concern over reproductive health problems, 
increased risk of cancer, and significant problems with infertility. 
While few effects of DES exposure were found, the surgical manipulation did 
reveal some differences. On the EZM, it was shown that the OVEX mice made 
significantly fewer entries into both the open and closed quadrants compared to the 
SHAM mice but this was in block 2 only, suggesting that the OVEX mice displayed more 
anxiety-like behavior and were less active than the SHAM mice during this specific time. 
In the OFT, more robust effects of the surgery manipulation were revealed. INTACT 
mice spent significantly more time in the center compared to the SHAM and the OVEX 
mice, made more entries into the center area compared to the SHAM and OVEX mice, 
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had significantly more activity counts in the center area than the SHAM and OVEX mice, 
made significantly more photobeam breaks in the periphery than the OVEX mice, reared 
significantly more in the center area compared to the SHAM and OVEX mice, and spent 
significantly less time frozen than the OVEX mice. All of these results imply that the 
INTACT mice displayed an overall decreased level of anxiety-like behavior compared to 
both the OVEX and SHAM groups. While these differences between the INTACT and 
OVEX groups were predicted, the disparities between the INTACT and SHAM groups 
were not expected and have been attributed to differences in circulating E2 that were not 
controlled (i.e., estrous cycles of mice were not tracked).  
Numerous reports concerning the influence of differing E2 levels (whether due to 
naturally circulating levels or administration of E2) on anxiety and depressive-like 
behaviors in rodents and symptoms in humans have been published. For example, 
Marcondes et al. (2001) has shown that rats in the proestrus phase of the cycle (i.e., high 
circulating levels of E2) spent more time in the open arms of the Elevated Plus Maze 
compared to rats in the diestrus phase (i.e., low circulating levels of E2). In addition, 
direct E2 administration to the amygdala in OVEX’d rats has been reported to induce 
anxiolytic behavior in the OFT and EPM (Frye & Walf, 2004a). Reports of clinical trials 
regarding treatment with hormone replacement in peri-menopausal women, young 
women with naturally low levels of E2, and women suffering from postpartum 
depression given E2 therapy have reported overall improved mood (Cohen et al., 2003; 
Smith, Studd, Zamblera, & Holland, 1995). Such results support the current study’s 
findings that INTACT mice displayed less anxiety-like behaviors in the OFT compared to 
the OVEX mice. However, these significant effects of surgery cannot be completely 
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attributed to the activity of estrogen alone. Other factors, such as the other hormone (i.e., 
progesterone) and neurotransmitter (i.e., serotonergic, GABAergic) systems that interact 
with E2 and also affect behavior could be at play. Further, the differences that were 
observed between the INTACT and SHAM mice could also be illustrating how powerful 
the effects of a surgical procedure can really be (i.e., anesthesia effects, stress of follow-
up injections and the recovery process).  
With regard to surgery-related effects in the tests of depressive-like behaviors, the 
current study showed that INTACT mice spent more time immobile compared to both the 
OVEX and SHAM mice but only during the last minute of testing in the TST. However, 
as seen in Figure 14, the mean difference in this final minute of the entire testing session 
was only 4 to 5 seconds; thus, it seems reasonable to conclude that no real differences in 
depressive-like behavior were observed in the TST. In the FST, OVEX mice spent less 
time immobile than the SHAM mice and had a greater swim distance compared to both 
the SHAM and INTACT mice. These results indicate that the OVEX mice displayed less 
depressive-like behavior compared to the groups with circulating E2.  
Others have reported effects of E2 administration in adult rodents and subsequent 
alterations in depressive-like behavior. For example, Rachman et al. (1998) reported that 
seven daily subcutaneous injections of estradiol benzoate in OVEX’d Sprague-Dawley 
rats resulted in a decrease in immobility compared to controls in the FST. Similarly, 
Estrada-Camarena et al. (2003) showed that OVEX’d Wistar rats given a subcutaneous 
injection of E2 also had a decrease in immobility time compared to control rats in the 
FST. There are few published reports concerning circulating E2’s influence on 
depressive-like behaviors in adult rodents. However, Vega-Rivera, Fernandez-Guasti, 
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Ramirez-Rodriguez, and Estrada-Camarena (2013) have shown that rats in proestrus 
displayed less immobility time in the FST compared to OVEX’d rats. It is important to 
note, though, that all of these investigations have used rats, while the present study 
utilized mice.   
Future Research 
 Because DES is such a potent estrogenic EDC that has been shown to affect 
various outcomes in brain tissue (i.e., size of sexually dimorphic regions) (Kubo et al., 
2003), it is still plausible that under the right circumstances, emotion-related behaviors 
could be perturbed by exposure, particularly during early development. Epigenetic 
research has associated EDCs and DNA methylation in the etiology of psychiatric illness 
(Abdolmaleky et al., 2004). It has been shown that early developmental exposure to DES, 
BPA, and other estrogenic compounds elicited altered methylation patterns in CpG 
islands in promoter genes, leading to modified gene expression in specific tissues (Li, 
Hursting, Davis, McLachlan, & Barrett, 2003). For instance, E2 has been found to reduce 
transcription of catechol-O-methyl transferase (COMT), one of many genes implicated in 
bipolar disorder and schizophrenia when hypomethylation occurs in its promoter region 
(Abdolmaleky et al., 2006; Jiang, Xie, Ramsden, & Ho, 2003). It has also been 
speculated that polymorphisms in genes that modulate epigenetic machinery and that are 
thought to promote genetic susceptibility for bipolar disorder and unipolar depressive 
disorder (i.e., the common MTHFR C677T polymorphism; MTHFR is also a crucial 
enzyme that controls one-carbon metabolism and regulates methyl donors, a primary 
epigenetic mechanism) in addition to DES exposure in utero could exacerbate the risk of 
developing such psychiatric illness (Krebs, Bellon, Mainguy, Jay, & Frieling, 2009; 
Peerbooms et al., 2011). Therefore, future research should further examine potential DES 
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effects on the epigenetic level and how such alterations may impact psychiatric outcomes 
including emotion-related behaviors.  
 Another consideration for future research in this area is in regard to examination 
of male offspring behavior. Though not as much has been reported concerning DES sons’ 
incidence of anxiety and depression disorders, it is still an important outcome to consider, 
especially because it has been shown that developmental exposure to other estrogenic 
compounds has resulted in a feminization of male emotion-related behaviors in rodents 
(Farabollini et al., 1999; Fujimoto et al., 2006).  
 In addition, previous work with DES has found that administration of this potent 
estrogen during early development has elicited alterations in sexually dimorphic nuclei of 
the brain. For example, Kubo et al. (2003) reported that early DES exposure in rats 
increased volume of the locus coeruleus (LC) in males and decreased LC size in females, 
thereby reversing the sex difference observed in control animals. Brain samples from the 
current study were collected and appropriately stored for later analyses. Thus, future 
assays of potential alterations of receptor expression and/or examination of changes in 
sexually dimorphic brain regions should be conducted. 
Finally, to obtain a more complete appreciation of the potential influence of 
exposure to estrogenic EDCs, future research should follow the suggested 
methodological criteria put forth by the US Food and Drug Administration (FDA) for 
BPA studies. Even though those standards were recommended specifically for BPA, they 
are also useful for research on other estrogenic EDCs. Because contact with most EDCs 
occurs through ingestion of contaminated food and water, oral administration is the 
preferred route. In order to detect a potential dose-response, it was recommended that at 
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least three relevant dose levels (not including control), ranging from a higher dose to a 
very low dose, should be employed. Further, additional sources of environmental 
estrogens should be controlled by using low phytoestrogen diets and utilizing glass water 
bottles and non-polycarbonate cages (U.S. Food and Drug Administration [U.S. FDA], 
2009). 
Limitations 
 The primary limitation in the current study was the lack of control for cycling E2 
in the SHAM and INTACT mice. Because their cycles were not tracked, these groups 
may have been in various stages of the estrous cycle, leading to increased variation in 
their performance on the behavioral tasks used, though it is presumed that other factors 
such as the stress and recovery from the surgical procedure itself may have impacted 
these results. However, there were still significant effects of surgery where the OVEX 
group displayed more anxiety-like behavior in the OFT, particularly in comparison with 
the INTACT group, and decreased depressive-like behavior on the FST.  
 Another shortcoming in this study was the large expanse of time between DES 
exposure in the dams and behavioral testing. Others have shown that depressive-like 
behaviors have been increased in rodents soon after parturition (Molina-Hernandez & 
Tellez-Alcantara, 2001). Because all the dams were ovariectomized, behavioral testing 
soon after exposure was not possible, as they needed a sufficient amount of time to fully 
recover from surgery as well as to allow circulating E2 to be reduced. However, the 
purpose of the current study in investigating possible behavioral changes in the dams was 
to see if DES exposure during pregnancy, a time of radical neurosteroid oscillation, could 
influence persistent postpartum emotion-related consequences. The results demonstrated 
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that administration of DES during this time did not elicit any significant behavioral 
changes in the dams.      
Conclusions 
 DES is not a safe compound, and exposure to this teratogen should be avoided as 
it has been shown to cause extremely detrimental effects, particularly in reproductive 
tissues and organs. In addition to such negative physical consequences, there have been 
many reports concerning developmental exposure to DES and its effect on alterations in 
emotion-related behaviors in lab animals as well as increases in rates of psychiatric 
illness in people that were exposed in utero, particularly DES daughters. However, this 
study has provided results suggesting that exposure to DES during late pregnancy did not 
alter emotion-related behaviors in either dams or female offspring. The lack of any 
meaningful DES-related effects on all tests of emotionality implied that the augmented 
level of anxiety and depression disorders documented in previous epidemiological reports 
is more likely due to current environmental factors regarding significant distress and 
concern about impending or existing health problems as opposed to DES exposure 
influencing brain organization and development. The current study did find several 
effects of the surgical manipulation that suggested OVEX mice displayed more anxiety-
like behavior in the OFT compared to mice with naturally circulating levels of E2. Such 
results suggested that alterations in E2 (in addition to other potential effects of the 
surgical procedure alone and/or changes in other hormone levels and neurotransmitter 
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